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CHAPTER I: 
Seven novel head-to-tail cyclic pentapeptides and pseudopentapeptides containing the 
arginine-glycine-aspartic acid (RGD) tripeptide motif were synthesized. All of the 
peptides were constructed using solid phase peptide synthesis. Functionalities of varying 
degrees of flexibility were incorporated into the cyclic peptide to pose as "linkers." 
Chosen as linkers for this study were the following: 3-aminomethylbenzoic acid 
("3AMB"), 4-aminomethylbenzoic acid,. aminocaproic acid, 8-amino-3,6-dioxaoctanoic 
acid, glycine-phenylalanine, glycine-glycine, and two pseudopeptides, GliP[CH~S]Gly 
and GIll'[CH2SlPhe. 
The cyclic peptide c(n-F-3AMB-RGD) was chosen for strucllural evaluation using 
nuclear magnetic resonance (NMR)I spectroscopy. Studies performed in 1007< DMSO-dh 
and DMSO-d6:H20 (2: I) allowed two structural constraints to be placed on the peptide in 
both systems to generate two working models. A comparison of the structures in the two 
solvent systems based on the NH-C'uH dihedral angles of Arg and Phe, revealed that a 
rather dramatic conformational change look place when water '0i<.lS added to the system. 
VIII 
Broadening of the Asp proton signals in 100(;( DMSO was indicative of restricted 
conformational exchange, possihly due to the formation of an internal Asp-Arg salt 
hridge. The signal hroadening is relieved upon the addition of :,07c water, indicating a 
disruption of the salt hridge. All of the hackhone amide protom, except for that of 
aspartic acid were found to display a temperature-dependent change in chemical shift, 
indicating that the Asp NH is involved in an intramolecular hydrogen hond in the 
presence of water, mm,t likely with the carhoxylate of its own side-chain. 
CHAPTER II: 
Ten new hone-targeted molecules were designed, synthesized, purified, and 
characterized, including two "universal" bone-targeting agents based on a model of the 
A-ring of tetracycline: 2-(2-(2-(3-carhamoyl-2-hydroxy-4-methoxyphenylamino)-2-
oxoethox y )ethox y )ethanam inium chloride and 5-(2 -(2 -(2-( 3-carhamoyl-2-h ydrox y-4-
l1lethoxyphenylamino )·2-oxoethox y)ethoxy)ethylamino )-5-oxopentanoic acid. To 
demonstrate the potential of the "univell'sal" bone-targeting agents, as well as produce 
potentially highly specific bone therapeutic or diagnostic agents., bone-targeted 
conjugates of estradioL doxorubicin, fluorescein, and genistein \\'ere synthesized. The 
resulting compounds preserved the putative pharmacophore while incorporating the 
hone-targeting elements. Each of these conjugates displayed significantly different 
soluhility properties and, consequently, demanded different methods of isolation and 
purification. 
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CHAPTER 1 
STUDIES OF CYCLIC PEPTIDES CONTAINING THE ARGIl\INE-GLYCINE--
ASPARTIC ACID PHARMACOPHORE 
I. BACKGROUND 
A. Peptides as Drugs 
Smce Merrifield's development of Solid-Phase Peptide Synthesis (SPPS) in the I 96(b, 
the pharmaceutical industry has had a vested interest in peptides as drug candidates. By 
exploiting the hiological diversity of peptide molecules, therapeutic agents such as HI\/ 
protease inhihitors, acetylcholine esterase (ACE) inhihitors, calcitonins, and vasopressin 
and somatostatin analogues have heen cultivated. As a class, peptides exhihit high 
biollogical activity, high specificity, and short half-lives, all of which make them valuahle 
for drug design. However, there is one major drawhack to employing peptides as 
pharmaceuticals: low hioavailahility (i.e. ahsence or oral activity and limited stahility). 
This prohlem is due largely to the fact that linear peptides in aqueous solution lack a 
fixed three-dimensional conformation. Therefore, peptides and peptidomimetics that 
have a more rigid structure arc currently being investigated for drug development. 
(Jackson, et ai, 1994). 
Through cyclization, peptides adopt a more restricted conformation, which may mimic 
that of pharmacologically active natural products (Rizo & Gierasch, 1992). At the 
moment there are several cyclic peptide drugs available on the market (sec Figure I). By 
iincorporating functionalities of varying degrees of flexibility into a cyclic peptide, one 
can systematically study the effect on the cyclic conformation and, consequently. its 
biological activity. Cyclizatiol1 also makes the peptides more resistant to proteolysis than 
their linear counterparts due to the lack of exopeptidase cleavage sites (Spatola, 1983). 
B. Rationale 
In the present study we have introduced a range of non-functionalized units, which we 
call "linkers," within a head-to-tail cyclic pentapeptide frame to act as dipeptide 
replacements. Such linkers allow not only for conformational adjustments, but also 
lipophilic modifications. Moreover, an appropriate linker can reduce the number of 
amide bonds in the peptide, further improving proteolytic resistance. 
The current project focuses on the synthesis of a series of novel head-to-tail cyclic 
pentapeptides and pseudopentapeptides containing the arginine-·glycine-aspartic acid 
(RGD) tripeptide motif all having the basic structure shown in Figure 2. RGD is known 
to be the recognition sequence of many integrin receptors. Integrins are receptors for 
extracellular matrix proteins such as fibrinogen. fibronectin, thrombospondin, and von 
Willebrand factor. Such protei ns are necessary for platelet adhesion and aggregation and. 
therefore. integrin receptors have been linked to angiogenic disease, osteoporosis. and 
restenosis. Many of the integrins recognize the tripeptide Arg-Gly-Asp (RGD)' which IS 
present in their respective ligands (Ruoslahti & Pierschbacher. 1987; Haubner. et ai, 
I997). Hence. RGD peptides and related peptides are useful for targeting therapeutic 





Figure 1: Examples of cyclic peptides currently on the pharmaceutical market. 
one of the best examples of an RGD-eontaining cyclic peptide that is commercially 
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Figure 3: INTEGRILIN', marKctL:d hy Millcnium Pharmaceuticak is an example or a cyclic RGD 
pcptidc that is currcntly hcing USL',j clinically. INTEGRILlN' i., an anticoagulant. 
It appears that different conformations of the RGD sequence playa significant role In 
integrin recognition and selectivity (Kostidis, et al. 2(04). Therefore, introduced within 
each of the cyclic peptides, 10 pose as "linkers," were a variety of nonfunctionalized 
structures (see Figme 4). Considering that these linkers may provide the bioactive 
conformation to the RGD pharmacophore, some of the compounds may he evaluated for 
competitive inhibition of fibrinogen binding (0 GpIIhIIIa integrin receptor. 






aminocaproic add II o 
o 
Hll\-------S~()II 
(;1),'111 CHzS 1(;ly 
Figure 4: Linkers used in R(,D reptidcs 
(the symbol "'P" indicates that the amide bond has been replaced with the bracketed moiety that 




c. Solid-Phase Peptide Synthesis 
All of the peptides were constructed using solid phase peptide synthesis (SPPS) 
(Merrifield, 1964; see Figure 5). Synthesis on the solid phase begins with the attachment 
of the C-terminal amino acid residue to an inert polystyrene-based resin. After the 
linkage of the first residue, the amine group is deprotected and the next amino acid is 
coupled. These steps of deprotection and coupling, with several wash steps in between, 
are repeated until the desired amino acid sequence has been assembled. Finally, the 
peptide is cleaved from the resin and the free peptide is released. In order to make a 
"head-to-tail" cyclic peptide, the N- and C-termini of the peptide are joined via an amide 
bond. This cyclization can take place before, during, or after the peptide cleavage from 
the resin (see Figure 6). 
For our studies we chose to use synthetic pathway B, as shown in figure 6. The 
anchoring of peptides to the solid-phase via an aspartic acid side-chain was a method 
introduced by Rovero, Quartara, and Fabbri (1991) and utilized by Spatola, et al to 
synthesize cyclic peptides libraries (Darlak, 1994; Spatola, 1996; Spatola & Crozet, 1996; 
Spatola, 1998). Since all of our desired peptides contained an aspartic acid residue, it 
was decided to proceed with the side-chain attachment and on-resin cyclization protocol. 
6 
AA. AA . ..... ,,,I 
AA . e e AA• 
e AA• e AA • 
Figure 6: Schematic Illustration or P,.;ptidc Cycli7.ation Options: Path A: cleavage from the solid phase with 
simultaneous cycliLatioll, Path B: on-resin cyclization followed by cleavage from the solid phase, Path C: 
cleavage from the solid phase followed by solution-phase cycli7.ation 
7 
The number and variety of condensing reagents available for amino acid coupling to 
form amide bonds has increased dramatically over the past several decades. Although 
carbodiimides have been the classical reagents of choice for peptide bond formation, 
many novel reagents have been developed to decrease racemization, increase yield, and 
lessen the chances for the allergic response caused by carbodiimide exposure. Today, the 
peptide chemist has available an array of activating agents that act via ester, anhydride, 
azide, or acyl halide formation, among others. The coupling agents used throughout the 
solid-phase synthesis of our peptides were benzotriazol-I-yloxytris( dimethyl amino )-
phosphonium hexafluorophosphate (BOP) and hydroxybenzotriazole (HOBt) (see Figure 
7). The coupling takes place as shown in Figure S. 
In order to make a "head-to-tail" cyclic peptide, or one in which the C-terminus of the 
peptide is covalently bound to the N-terminus, we used the strategy of attaching the C-
terminal residue to the solid support via its side-chain. This way, the C-terminal 
carboxylic acid functionality is left open for later cyclization. Since all of the peptides 
synthesized for this study contained the arginine-glycine-aspartic acid motif, the side 
chain of the aspartic acid residue lent itself well for resin attachment. A hydroxymethyl-
functionalized resin was chosen for all of the cyclic peptide syntheses. 
8 
hydroxybenzotriazole (HOBt) 
benzotriazol-I-yloxytris( dimethylamino )-phosphonium hexafluorophosphate (BOP) 
Figure 7: BOP and HOBt coupling agents 
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Figure 8: Mechanism of BOPIHOBt Peptide Coupling. In the presence of base. BOP reacts with the 
carboxylic acid to form an acylphosphonium salt. This highly reactive species can then either be attacked 
directly by a free amino group (as shown with the green arrows) or can go on to form an active ester by 
reacting with HOBt (red arrows), The active ester will be converted to the amide by attack or a free amine. 
D. Peptide design 
An assortment of linkers was selected for incorporation into the cyclic peptide series (see 
Figure 4). The linkers vary in structure, from the rigid aminomethylbenzoic acid 
moieties to the flexible aminocaproic and 8-amino-3, 6-dioxaoctanoic acids. Varying 
degrees of rigidity should lead to varying conformational consequences. Also, insertion 
10 
of these different linkers into the cyclic RGD peptides should induce changes in 
lipophilicity. Further, we incorporated the pseudopeptides GlytJiICH 2S]Gly and 
Gltl'[CH2S ]Phe (where "tp" indicates an amide bond replacement with the group 
contained in brackets) as linking units because of their moderate flexibility and stability 
towards enzymatic degradation. We also synthesized the peptide analogs containing-
Gly-Gly- and--Gly-Phe- linkers for hiological activity comparison. 
Degrado and coworkers synthesized and studied a series of cyclic RGD peptides 
(Jackson, et ai, 1994; Bach, et ai, 1(94). The two most potent of these compounds were 
found to be c(D-Ahu-N-MeArg-Gly-Asp-3AMB) and c(Il-Val-N-MeArg-Gly-Asp-
3AMB). It was found that the features that most restricted peptide conformation, and 
hence were important for tight binding to the IIolIIIa integrin receptor, were the 0-
chirality at position I, N-methylation of the arginine residue, and the incorporation of the 
3-aminomethylbenzoic acid (lAMB) motif. With these ideas in mind, we chose to study 
our 3AMB-containing peptide more closely for structural evaluation. 
II 
n. EXPERIMENTAL 
General Methods. All chemicals and solvents (reagent grade) were purchased from 
Peplides InternationaL Advanced Cherntech, Fisher Scientific, or Sigma-Aldrich unless 
otherwise indicated and were used without further purification. Boc-3-
aminomethylbenzoic acid was purchased from Bachem. Solvents were purchased from 
Fisher Scientit'ic or Sigma-Aldrich and distilled as needed. 
The crude peptides were all purified via preparative reverse·-phase HPLC on either a 
Varian 5000 liquid chromatograph with a column from Vydac or Waters instrument with 
a NovaPak column_ All peptides were subjected to mass spectl'Oscopy using an Applied 
Biosystems Voyager DE-Pro MALDI-TOF instrument in reflector-positive mode with 
delayed extraction and a a-cyano-4-hydroxycinnamic acid matrix on a stainless steel 
plate. Nuclear magnetic spectroscopy studies were performed on a Varian INOVA 500 
MHz spectrometer. Substitution level of Boc-aspartic acid to the hydroxymethyl resin 
was determined by the methods described by Green and Bradley (1993)_ 
1. Synthesis of Boc-Glycine'f'[ClIzS]phenylalanine (Scheme O. 
a. tert-butyl 2-hydroxyethylcarbamatt{~ (1). Ethanolamine (5 mL, 82.8 mmol) was 
dissolved in DCM (150 ml) and was treated at room temperature with triethylamine 
(11.6 mL, 82_8 mmol) and di-tert-butyl dicarbonate ( 18_05 g, 82.8 ml11ol) for 18 hours at 
room temperature. After this time, more eli-ten-butyl dicarbonatc (4_50 g, 20.7 mmol) 
was added to the solution, as thin-layer chromatography indicated that the reaction had 
not gone to completion. After four addittional hours of stirring, the reaction was 
complete_ The reaction mixture wa" with saturated sodium chloride 3X and I' N Hel 3X. 
The organic layer was then dried over sodium sulfate, filtered, and concentrated via 
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rotary evaporation Ito yield 1 ( 11.2 g. transparent oiL ~4.2(7r': I H NMR (500 MHz, CDeII ) 
o 1.39 (s. 9H, t-hutyl), 3.42 (d, 2H. C1-b). 4.10 (t. 2H. CH2), 4.X9 (hI's, I H, I\H)). 
b. 2-(tert-butoxycarbonylamino )ethyl 4-methylbenzenesulfonate (2). 130c-
ethanolamine (4.14 g, 25.4 mmol) and triethylamine (7.9 mL, 56.~ mmol) were dissolved 
in DCM (50 mL) and cooled in an ice bath. p-toluenesulfonyl chloride (5.:17 g. 2X.2 
mmol) dissolved in DCM (50 mL) wa~, added. The reaction mixture was stirred in an ice 
bath for I hour and at amhient temperature for 4~ hours. The reaction mixture was then 
filtered and washed with DCM. The filtrate was washed with 0.25 N sulfuric acid 3X, 
saturated NaCI :IX, and dried over Na2S04 and filtered. The solution was concentrated 
under vacuulll to yield an oil. The oil was triturated in hexane/ethyl acetate and a white 
solid precipitated. The mixture was kept at 4°C overnight then the solid product 2 was 
coBected via vacuum filtration. (3.35 g, white solid, 41.9%, mp: 63°C; I H NMR (500 
MHz. CDCI,) 0 1.42 (s. 9H, t-hutyl), 2.47 (s, 3H, OCH,), 3.25 (t, 2H. CH2), 4.08 (d, 2B. 
Cl-h I, 4.g5 (hI's, I H, NH). 7.3~ (d, 4H, aromatic), 7.~ I (d, 4H. aromatic)). 
c. (R)-2-bromo-3-phenylpropanoic acid (3). D-phenylalanine (6.6 g. 41 rnmol) and 
potassium hromide (28.39 g. 239 mmol) were dissolved in 2.5 N H2S04 (75 mL). The 
solution was cooled in an icc-salt hath and sodium nitrite (4.25 g. 62 mmol) in water (25 
mL) \vas added dropwise. The solution was stirred continuously overnight at ambient 
temperature. The reaction solution wa~, extracted with ether 3X. The organic layers were 
combined and washed with 2.5 N H2S0~1 4x and water 3X, then dried over Na:2S04 and 
filtered. The ether layer was then concentrated to give 3 (~.31 g, yellow oiL 8~.6lk; I]H' 
NMR (500 MHz. CDCI,) 0 3.30 (d of d, I H, benzylic). 3.5 (d of d. I H. benzylic). 4.40 rt. 
I H, u-CH). 7.25 (m, 5H, aromatic), 9.00 (br s, IH, COOH)). 
d. (S)-2-mcrcapto-3-phcnylpropanoic acid (5). To a solution of 3 (7.34 g, 33.4 mrt1ol) 
in dry acetone (15 mL) was added via dropwisc addition a solution of thiourea (2.53 g. 
33.4 mmol) in dry acetone (45 mL) at room temperature. After stirring overnight, the 
solution was subjected to rotary evaporation to allord the isothiouroniulll sallt 4. The S(llt 
was then dissolved in water (brought to pH 10 by the addition of 10';', sodium hydroxide) 
and the solution was set to reflux for 7-R hours. Arter cooling to roOIll temperature, the 
solution was extracted with EtOAc 3X and the aqueous layer was then acidified to pH 1.5 
and extracted with EtOAc 3X. The organic layer was dried over Na2S04, filtered, and 
evaporated til afford 5 (3.68 g, dark yeUow oil, 60.7<J'r,; IH NMR (500 MHz, CDC],) () 
2. 10 (d, I H. SH), 2.94 (d of d, 2H, benzylic), 3.15 (d of d, I H, benzylic), 3.54 (q, I H, et-
CH). 7.25 (m, 5H, aromatic), 8.34 (or s, I H, COOH». 
c. 2-(2-(tert-butoxycarbonylamino )cthylthio )-3-phcnylpropanoic acid ("80c-
GlyYJICH2SlPhe", (». Sodium ethoxide was prepared oy dissolving sodium metal (536 
rng) in aosolute ethanol (12 mL). Compound 5 (1.5 g, 8.2 mmol) was dissolved in 
absolute ethanol ( 15 mL) and added to the sodium ethoxide solution. The solution was 
then warmed to 6()c'C under argon. Compound 2 (2.59 g, R.2 mmol) dissolved in absolute 
ethanol (20 mL) and dry THF (20 mL) was added dropwise over a 2-hour pel·iod. Artel' 
stirring for 3.5 hours at 60°C, the solvent was stripped under vacuum and the resulting 
residue was taken up in water (15 mL). The aqueous solution was washed with ether ]X, 
and then acidified with 2 N H2S04, The product was then extracted with EtOAc 3X, the 
organic layers combined and dried over Na2S04' and the mixture filtered. The filtrate 
was concentrated under vacuum to give an oily residue. The residue was triturated in 
ether with a few drops of dicyclohexylarnmonia until a precipitate 'Nas formed. The 
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mixture sat overnight at 20°e. The precipitate was collected and recrystallized from 
EtOAc. The resulting solid was dissolved in a minimal amount of 0.2 N H2S04 and was 
extracted with ether 3X. The ether layer was dried and evaporated to give 6 ( I. 71 g, 
hrown oiL 63.8<;'(; MALDI peak (n+l+ Na): 348.3514, (n+I+K): 364.32(9); IH NMR 
(500 MHz, CDChl 8 1.46 (s, 9H, t-hutyl), 2.7 and 2.82, (Ill, 4H, CH2 ), 2.94 ,md 3.22 (d 
of d. 2H, henzylic), 3.53 (t, I H, (X-CH), 4.85 (s, I H, NH), 7.28 (111, H, aromatic». 
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Scheme 1: Synthesis of Boc-Gly'PICH2SIPhe. 
2. Synthesis of Hoc-Glycine'f1[CH2S]Glycine (2-(2-(tert-
butoxycarbonylamino)ethylthio)acetic acid; 7, Scheme 2). Freshly shaved sodium 
metal (245 mg) was dissolved in ahsolute ethanol (5 mL). To this solution was added 
thioacetic acid (351 mg, 3.8 1TI1l10i) in ahsolute ethanol (5 mL). The solution was warmed 
to 6()OC and compound 2 (scheme I; 1.2 g, 3.8 I11mol), dissolved in anhydrous ether (20 
mL) and dry THF (20 mL), was added dropwise over a I-hour period. The mixture was 
stirred at room temperature under nitrogen for 4 hours. The solwlion was then evaporated 
and taken up in water (15 mL). The aqueous solution was extracted with ether 3X, then 
acidified with 2 N H2SO.!. The product was extracted with EtOAc 3X, the organic layer:~ 
comhined and dried over Na2S04, and the mixture filtered. The filtrate was concentrated 
under vacuum to give an oily residue. The residue was triturated in ether with a few 
drop-; of dicyclohexylamlllonia until a precipitate was formed. The mixture sat overnight 
at 20°C. The precipitate wa" collected and recrystallized from EtOAc. The resulting 
solid was dissolved in a minimal amount of 0.2 N H2S04 and was extracted with ether 
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3. Solid-Phase Peptide Synthesis of Cyclic RGD Peptides. All peptides were 
synthesized manually using 10 mL rritted syringes as the reaction vessels. To monitOl' 
peptide deprotection/couplings, a Kaiser test kit was purchased from Sigma-Aldrich. 
Kaiser tests were performed after each deprotection and coupling step as follows: 
I. A few heads were collected from the resin sample and placed in a test tuhe. 
3 drops of each of the following reagents was added to the test tuhe: Ninhydrin 
Solution, Mf in Ethanol; Phenol Solution, ~80(k in Ethanol; Potassium cyanide 
Solution, in Pyridine. 
3. The test tuhe was heated in a hoiling water hath for 5 minutes. 
4. A positive Kaiser test yields hlue heads; a negative test yields colorless or yellow 
heads. 
Neutralization of the resin following removal of the Boc-group was performed ill sitll 
hy using a 2: 1 ratio of hase:carhoxylic acid during the coupling steps. 
The following describes the synthesis of the peptide c(n-Phe-3-AMB-Arg-Gly-Asp) (see 
Scheme 3). All other peptides were synthesized analogously. 
a. i. Boc-Aspartic Acid Internal Anhydride. Boc-aspartic acid (5.00 g, 21.5 mmol) 
was dissolved in 25 mL of ethyl acetate. In a separate flask, dicyclohexylcarhodiimide 
(DeC) (4.42 g, 21.S mmol) was dissolved in 3 mL of ethyl acetate. The Dec solution 
was then added dropwise to the Boc-asp solution while chilled in an ice hath. The 
reaction proceeded for I hour at O°C and then at ambient temperature for I hour. The 
mixture was filtered, the filtrate evaporated, and a white solid was obtained. The solid 
product 8 was lIsed immediately in the next step. 
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ii. Boc-Asp-OFm. Product 8 was dissolved in 25 ml of tetrahydrofuran (THF). To this 
solution was added 4.22 g (21.5 mmol) of f1uorenylmethano) and diisopropylethylamine 
(OlEA:: 3.75 ml, 21.5 mmol) while the solution stirred. The reaction was allowed to stir 
overnight at room temperature. The solvent was then evaporated to yield an oily product. 
The oil was taken up in EtOAc and acidified to pH = 2 with 1 N He!. The organic layer 
was washed 3X with IN Hel, 3x with brine, and then dried over sodium sulfate. After 
gravity filtration, the filtrate was concentrated under vacuum and a white powder was 
obtained. The solid was recrystallized with hexane and EtOAc to give product 9. Yield: 
4.69g (53(lr). mp 167.5-169.5°C. 
b. Attachment of Boc-Asp-OFm to Hydroxymethyl Resin. 3.00 g of hydroxymethyl 
resin (1 mmollg loading capacity) was swollen in 25 ml of dichloromethane (OeM) for 
1 hour. In the meantime, 9 (2.47 g, 6.00 mmol) and di-tert-butyl dicarbonate (1.31 g, 
6.00 mmol) were dissolved in 10 mL of oeM and added to the swollen resin. Pyridine 
(0.49 ml, 6.00 mmol) was then added to the reaction mixture and it was allowed to stir 
overnight at room temperature. The resin was filtered and washed 3X with OeM, 2X 
with methanol, 3X with OeM, 2X with ether, and 2X with hexane. The substitution level 
of product 10 was determined to be 0.69 mmol per gram. Yield: 4.05g. 
c. Capping of Hydroxymethyl resin. Product J 0 (4.05 g, 0.31 mmol of uncapped resin) 
was swollen in 25 ml of OeM for 1 hour. To the resin was added acetic anhydride 
(0.213 ml, 3.72 mmol) and pyridine (0.301 ml, 3.72 mmo\). The reaction mixture was 
stirred for 30 minutes, and then the resin was washed with OeM and methanol. The 
capping reaction and washing steps were repeated twice more. A final oeM wash OX) 
prepared the resin, 11, for use immediately in the next step. 
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e. i. Hoc-deprotection of Aspartic Acid. Product 11 was stirred in 25 mL of 
trifluoroacetic acid: OCM: anisole (45:50:5) for 45 minutes. The resin was washed with 
OCM 3x, methanol 2X, and DCM 3X. After performing a Kaiser test and achieving a 
positive result, the resin-bound product 12 was washed with DMF 3X in preparation for 
the next coupling step. 
ii. Coupling of Boc-Glycine to Aspartic Acid. Boc-glycine (1.09g, 6.21 mmol), HOBt 
(0.839 g, 6.21 mmol), BOP (2.75 g, 6.21 mmol), and OlEA (2.16 mL, 12.42 mmol) were 
stirred in 10 mL of OMF for 90 seconds. The solution was then added to swollen product 
12 and allowed to stir at room temperature for 2 hours. The resin was washed with DMF 
3X, methanol 2X, and DCM 3X. A Kaiser test was performed and was negative, 
indicating that product 13 was formed. 
iii. Peptide Chain-Elongation. Boc-deprotection and suhsequent coupling were 
repeated until the desired Boc--protected linear peptide sequence (structure 14) was 
achieved. In the ca:~e of the peptide containing the mini-PEG linker, Fmoc-mini-PEG 
was used and, therefore, N-terminal deprotection was performed with 209r piperidine in 
DMF. Since the C-terminus was also Fmoc-protected, the mini-PEG residue was at the 
N-terminal position of the peptide before cyclization. This differs from the other peptides 
in this series which all have phenylalanine N-terminal residues. 
f. On-lResin Head-to-Tail CyclizaHon of the Peptide. In order to cyclize the linear 
peptide, the C-terminal Fmoc-group was first removed with 209r piperidine in OMF 
followed hy Boc-deprotection of the terminus with a 459r TFA. solution. The coupling 
agents BOP and HOBt (3 molar equivalents of each) were then added to the resin 
mixture, along with 6 molar equivalents of OlEA, and the reaction was allowed to stir 
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overnight at room temperature. After the resin was washed with OMF 3x, methanol 2X, 
and OCM 3X, a Kaiser test was performed. Most cyclizations had to be repeated 3 to 4 
times before a negative Kaiser test was achieved. Structure 1.5 shows the head-to-tail 
cyclic resin-bound peptide. 
g. HF cleavage of Cyclic Peptide from Resin. To remove the cyclic peptide form the 
solid support, the resin was dried overnight and then placed in an HF reaction vessel, 
along with a stir bar and -0.5 mL of anisole. The vessel was cooled in a dry ice-acetone 
bath for 20 minutes .. The vessel was then evacuated for 5 minutes and anhydrous 
hydrofluoric acid was introduced (-10 mL per gram of resin). After completion of the 
HF gas transfer, the reaction vessel was brought to room temperature and allowed to stir 
for 3 hours. The ve~sel was then evacuated for 1.5 hours. The resin was removed from 
the reaction vessel and washed with diethyl ether over a fritted funnel. Finally, the 
peptide was extracted by rinsing the resin on the frit with 25';( acetic acid 5X. The 
aqueous extract was frozen in a dry ice/acetone bath and lyophilized to give a white solid 
product 16. 
h. Purification of Cyclic Peptides. All peptides were purified via preparative reverse-
phase HPLC using a C 18 column. The peptides were eluted with a 10-50';( acetonitrile 
gradient, with the exception of the peptide containing the 8-amino-3, 6-dioxaoctanoic 
acid linker which required a 2-50(,lc acetonitrile gradient. The gradients ran over a 30-
minute period and the peptide elution was monitored via UV absorbance at A=220 nm. 
The appropriate fractions were pooled and lyophilized to give the products discussed in 
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III. RESULTS AND DISCUSSION 
A. Synthesis 
All of the cyclic peptides products are summarized in Table 1. Figure 9 shows 
schematic representations of the peptides. Note that peptides PI-P7 have the structure 
cyclo(F-X-X-RGD) while peptide P8 has structure cyclo(X-X-A-RGD), where "X-X" 
represents the linker moiety. The differences in the two sequences arose from the 
incompatibility of protecting groups during the solid phase synthesis using the 8-amino-3, 
6-dioxaoctanoic acid linker. 
C-terminus of G 










I I X, /A~ 
X 
B 
Figure 9: Schematic representations of cyclic peptides. Peptides P I·P7 Crable 1) are represented as A. 
while peptide PX is represented hy B. ··X·X" = linker. 
The peptide containing 4-aminomethylbenzoic acid (peptide P2, Table 1) was 
unattainable as a cyclic molecule. The rigid, linear 4-AMB residue did not lend itself 
well to ring closure. After seven consecutive reiterations of reagent addition, stirring, 
filtering, and wash ~teps over a period of one week, a positive Kaiser test was still 
ohserved. Howevct', inclusion of the bent 3-AMB molecule did allow for cyclization, as 
seen in peptide PI (Table 1). 
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Notice that the peptides are not composed of only four residues (as originally 
proposed), but rather five residues. It was discovered that the ring-closing step with only 
four residues was unsuccessful, most likely due to torsional strain. Such strain was 
relieved with the addition of another residue. In all but one of the peptides this fifth 
residue was chosen to be phenylalanine. 
It was also found that a "0" configuration at the fifth position rather than an "L" 
seemed to be preferred for ring closing. Therefore, peptide PI, containing the 3-AMB 
linker, was synthesized with D-Phe at the N-terminal position. Although the 3-AMB 
peptide was still obtained in low yield, the change in configuration at this position 
resulted in an improvement from less than 1 ric) to nearly 5% purified yield. The 
preference of the O-amino acid at position 5 is most likely due to sterie interactions that 
are lessened during ring closure. Figure 10 shows a pictorial depiction of the differences 
in steric interaction~ when a O-residue is used in place of an L. 
Though all of the peptides were obtained in seemingly low yields., it is not uncommon 
in the literature to find a wide range of yields for cyclic peptides, For example, Jackson, 
et al (1994) report yields of similar cyclic peptides spanning from 3.8r;;~ up to 72.27('. It 
appears the yields of these small cyclic peptides are very sequence dependent, most likely 
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Table 1: Data from Synthesis of Cyclic Peptides. Mass s[1l'ctral data \\as ohl<Jined alter one-point caiihration 
of the matrix peak. 
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Figure 10: Three-dimensional view of how side-chain steric interactions in a peptide containing L-
phcnyaJanine (left) can be relieved when D-phcnyJaJanine is used instead (righ t). 
Matrix-assisted laser desorptionlionization time of flight (MALDT-TOF) mass 
spectrometry analysis of each crude cyclic peptide product revealed various side-products 
that also contributed to low purified yields. The most common of these side-products 
were internal succinimides and dimeric species. As depicted in Figure 11 , it is possible 
for an aspartic acid residue to form an intramolecular succinimide with a neighboring 
backbone amide group. Such a product is characterized by a MALDI-TOF peak of mass 
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Figure 11: Formation of internal succinimide hy aspartic acid side-chain. 
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When synthesizing a head-to-tail cyclic peptide via solid-phase methods, a possible 
side-product is a so-called cyclic peptide "dimer." Figure t2 shows how this dimer can 
form. The construction of higher order oligomers is also possible in an analogous 
fashion. To prevent such side-products from forming, peptide chemists often employ 
high-dilution techniques when using solution-phase chemistry, to reduce the probability 
that two linear peptide molecules would come into close contact and form oligomeric 
species. To accomplish this task on the solid phase (as was done for this project) the 
resin is not loaded to full capacity. Still, dimeric side-products were observed in nearly 
all of the cyclic peptides, as identified by a MALDI-TOF peak of two times the desired 
molecular weight. These dimers can be isolated, in addition to the desired monomeric 
species, by means of chromatographic separation. The RP-HPLC chromatogram of the 
crude 3-AMB-containing peptide (Pt) is shown in Figure 13. In the interest of biological 
activity as well as structural comparison, we decided to isolate the monomeric 3-AMB 
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Figure 13: Above: RP-HPLC chromatogram of crude peptide PI. 
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B. Structural Studies of Peptide PIa 
I. Studies in 100% DMSO 
The monomeric cyclic peptide PIa (Figure 14) was chosen for structural evaluation 
using nuclear magnetic resonance (NMR) spectroscopy. Because the peptide was 
insoluble in water, it was first dissolved in DMSO-d6. The first spectra obtained are 
shown in Figures 15 and 16. The protons were assigned from COSY, HMBC/HMQC, 





Figure 14: The monomeric cyclic pcptidt;: PIa. 
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Table 2: Summary of ' H Chemical Shifts 
DMSO-d6 at 37
cC (8 mM) 
Proton Shift (ppm) 
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Figure 16: Fingerprint region ofTOCSY spectrum arPIa in 1007< DMSQ·d, (8mM) 
The so-called "fingerprint" region of a TOCSY (TOtal Correlation SpectroscopY) 
spectrum is used to quickly assign the chemical shifts of amide and aliphatic protons of 
peptide or prolcin residues. The correlations observed in this region arise from th rough-
bond coupl i ng of backbone amide protons with the neighboring protons attached to 
carbon·a , carbon-~, and so on, normally extend ing out to the y- or 0- position (see Figure 
17). The fingerprint region of a COSY (COrrelation SpectroscopY) spectrum on the 
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Figure 17: Through ~ hond (.;o upling in teractio ns in a TOCSY experiment can be observed between 
the amide backhone proton and the protons 0 11 neighhoring carbons atoms. Normally the coupling 
can be observed out to the y- OJ' 5- ros it ion. The COSY experi ment shows onl y cnur lings between 
the ami de NH alld its immedi ate neighbor, the a-proton. 
To differentiate between a spi n system like aspartic acid, which has both a and ~ 
protons, and one like glycine or 3-AMB, which has two a protons, someti mes only a 
TOCSY experiment is necessary. However, in small , constrained peptides, the two a 
protons , being diastereotopic, are like ly to have disti nc t chemical shift s, as they are held 
in diffe rent magnetic environments. For a similar peptide , Bach et al (1994) reported 
alpha-proton resonances fo r Gly at 3.53 and 3.99 ppm and for 3-AMB at 4.06 and 4.52 
ppm. Consequen tl y, an ala system will be indistinguishable from an alp system in the 
TOCSY spectru m. Tn these cases, the COS Y experiment may he used to distinguish the 









"u/P" spin system nonequivalent "o/u" spin system 
Figure 18: A TOCSY experimen t alone ca nnot he lI ,cd to e1ilTe,en ti ute these two systeills. Howe"er. 
the two spin SYS[UIllS wil l have distinct appearances in i.t COSY srcctrulll , as corre lati ons will only ht..! 
obscl'vl:d between ndghhoring protons (red) . 
If all five res idues of Pia were apparent in the TOCS Y and COSY spectra, one would 
expect to observe two u/a systems, corresponding to glyc ine and 3-AMB, and three a/~ 
systems, corresponding to arginine, phenylalanine, and aspart ic acid . When assigning 
these spectra, however, it was noted that all of the residues except fo r aspartic acid could 
be clearl y di scerned. Argi nine was easily distinguished from the other res idues in the 
TOCS Y spectrum, as couplings were observed between its amide proton and Hu, Hn, Hy. 
and even H6 (see Figure 16). The ass ignments of phenylalan ine and 3-
aminomethylbenzoie ac id were confirmed by observed correlations between aromatic 
carbons and aliphatic alpha protons in the HMQC/HMBC spectra. It was apparent that 
some of these aliphatic protons corresponded to an a/a system (3-AMB) and some to an 
a/~ system (Phe). Figure 19 shows the HMBC corre lations. The remaining spin system 
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Figure 19: An HMBC speclrum of peptide Pl. in 100% DMSO-d, (8 mM) . Couplings were observed 
bel ween phenylalanine Hn and aromal ic carhons. Similar couplings were observed wilh 3-
aminomelhylbenzoi c acid Ha and aromatic carbons. These correlations confirmed the assignment or the Phe 
and 3-AMB NH prolons. 
It was speculated that the amide proton of aspartic acid was the peak around 07.8 ppm, 
but the TOCSY signal intens ity for the through bond couplings of that proton were found 
to be quite weak. The intensity of the NH to H" correlation appeared to be more 
pronounced in the COS Y spectrum. Figure 20 highlights the couplings observed between 
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Figure 20: Weak through-hond couplings 
were observed between a proton at (i7 .8 ppm 
and aliphatic prolOns in both the TOCSY and 
DQCOSY sflCctra of Pia in 100';1 DMSO-d(, 
(KmM ). 'I'he proton was !-.pcculalCd to be the 
backbone amide proton of asparl ic acid. 
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2. Studies in a Mixed Solvent System 
When the solvent system was changed from 100% DMSO·d(, to DMSO·d(): H20 2: I, 
some notable changes were observed. The most remarkable of these changes was that all 
five amide protons were clearly visible in the DMSO: H20 system, as observed in the 
TOCSY spectrum (Figure 21). 
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Figure 21: All live Hillide proton, were ctear ty visible in the 




Another notable difference was the upfield shift of a 3-AMB aromatic proton from about 
88.3 to approximately 07.4, as shown in Figure 22. 
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Figure 22: The ~ -aminnl11t!lhyl benloic add proton highlighted in hluc l'l1akl!s an upfit.!ld shift when water 
is added to th l! solvent system, 
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Little data could be gathered on thc monomeric peptidc species in the mixed solvent 
system, as suppression of the water signal under these conditions was difficult to 
opt imize and many of the peaks in the two-dimensional spcctra were not assignable. 
However, by comparing the TOCSY spectrum taken at 100% DMSO-d6 to that at 309C 
water, some tentative assignmcnts could be made. The backbone amide proton of 
arginine was clearly still the most downfield at about 68.96, so assignments could be 
made for some of the side-chain protons (Figure 23). 
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Figure 23: TOCSY fln gerprinl of Pla. DMSO·do: H20 (2: I: 5 111M), 16 'C The nrgini ne backhone 
amide proton \Vas still the furthest downficld. mHking it easy to identify Arg through-hand couplin g~. 
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Taking into account the splitting pat terns of the am ide protons and the fact that the 
protons in the a-position of an amino acid arc typically more deshiclded than those in the 
p-position , it was surmised that the two amide protons at - 88.4 and - 88.2 belonged to ala 
spin systems, namely glycine and 3-AMB. The remain ing two protons in the amide 
region were then assumed to belong to the two alp systems, phenylalanine and aspartic 
acid. 
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Figure 24: TOCSY fingerprint 
region of P I u. DMSO-d,,: 11,0 
(2: I; 5 IllM ). 16 ·'C. Two ala and 
two alP spin sy~tcl11s were 
postul ated hased on the aliphatk: 
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In trying to deduce which a/a system was Gly and which was 3-AMB, it was 
reasoned that the chemical sh irt of the 3-AMB amide proton should remain furt her 
downfield than the Gly amide proton. Therefore, the respective assignments of the 3-
AMB and Gly amide protons were speculated to be 08.4 and 08.2. 
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Figure 25: ringerprint region ufr la, 
DMSO-d,, : H20 (2: I; 5 111M). 16' C. The 
3-AMB NH and Gly NH were tentatively 
assigned in the mi xed solve nl system. 
The assignment of the Phe and Asp amide protons were a little more straightforward, as 
only one set of I-ln protons appear to have distinct chemical shifts. Since the Phe Hil 
protons are adjacent to an aromatic ring, it would make sense that these two ~-protons 
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could be held in magnetically different environments. Hence, the amide protons or Phe 
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Figure 26: Fingerprint region of 
DMSO·d,,: 11 ,0 (2: I: 5 mM), 16' 
PIn, 
C. 
The assignment 01' the Phc NH wa s 
based on the distinct , hil'ts ol'tl1e t wo H~ 
• g up r mlons. Thi s indicates a e l l, 11"0 
next to an aromat ic ring. 
The tentative ass ignments of the protons of the pept ide in the mixed solvent system at 
16 °C are tabulated below (Table 4). 
residue HN' H: 
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Tuble 4: Prolon (; h ~ l11i c al shins Ill' Pia in DMSO·d(,: 
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H20 (2: I : 5 111M) at 15'e. 
.JI\ (~( '" 
8.55 
3. Structural evaluation of PIa 
A. 100% DMSO 
By calcu lating the dihedral angles of the NH-CuH froll1 the l -coupling constants, two 
st ructural cons traints could be placed on the molecule. Thc Karplus equation. shown 
below with coefficients from Bystrov (1973), calculated the dihedral angle for both Phe 
and Arg NH-CuH was found to be _156°. ChemOffice Chem3D Ultra software with 
MM2 energy minimization generated the structure in Figure 27. 
3J = Acos2(q» + Bcos(q» + C 
Kal'plus Eq uation 
(A = 9.4, B = -1.1, and C = 0.4) 
Al'g 
Figure 27: Proposed Slructure of Pia in IOO'if DMSO generated froll1 MM2 minimi lat ion. 
High li ghted in arc the backbone NH and the C" and H,. atoms or Arg and Phe. By calcu lating 
the diht.xlrnl 3ng l ~ .., or Phe and /\rg from the J-coupling constants. two constraints were placed on the 
(.; onfOI'I11HI iOIl . 
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Observed ROESY interactions support the proposed structure, A fairly strong NOE was 
observed between the 3AMB ring proton a (Figure 1) and the Arg NH, Another NOE (of 
weaker intensity) was observed between the proton a and the alpha proton of Phe, Figure 
28 depicts these interactions, 
,1\ p'lI 
II:' 
Figure 28: The gct1cfalud structure corresponds Wl!lI with observed ROESY inlcrocliOlls (hlu !..! 
"rrows) between the 3-AMB ring rrOLOn and H" or Phe und the NH rrOlOn or Arg highlighted in 
Unfortunately, no conformational data could be gathered about the Asp residue, as the 
corresponding signals were weak, 
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B. DMSO: H20 (2:1) 
Using the Phe and Arg NH-C"I1 J-coupling data in the mixed solvenl system, a 
second struclllre could be generated. The .JNII-CuH values or 8.55 Hi and 7.81 Hz 
corre,ponded to dihedral angles of 151 ° and 148° for Phe and Arg, respectively. As in 
100'70 DMSO, no other J-coupling constants could be measured because Ihe splitting 
patterns were unclear. The Figure 29 shows the structure using the two constraints. 
Figure 29: Propo.,ed structure or peptide Pia in DMSO:H,O (2 : I) . Highlighted in am the 
hadbone NH and the Co and H" alOl11s or Arg and Phe. l3y calculating the dihedrul angle s or Phe and 
Arg I'wmlhe J-coupling cono;tanl'), two constraints were placed on th~ conformation . 
The amide proton chemical ,hins in the mixed solvent system were round to display 
tempcrature-dependence. Figure 30 shows the t J-I NMR spectrum of the peptide aI 15 , 
25, and 37°C. The shifts of each amicie proton were plotted at various temperatures to 
determine the tcmperalure coefficient of each (Figure 31). 
Temperature coefficients (i. c. L'>61L'>T) can be informative tools for determining 
hydrogen-honding interactions (Kessler, 1982). A temperature coefficient of greater 
50 
absolute value than 4 x 10-3 ppm indicates an intennolecular hydrogen bond (e.g. with 
solvent), as these interactions are disrupted with increased heat. The proton becomes 
more shielded as temperature increases and moves upfield. If the absolute value of the 
coefficient is found to be less than 2 x 10-3 ppm, intramolecular H-bonding is suggested, 
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Figure 31: Plot of NH shifts as a function of temperature. Temperature coefficients were taken as the 
slope of the linear trendlinc for each NH. 
From the large negative temperature coefficient measured for the Arg NH (-6.8 x 10-3 
ppm), it is apparent that this proton interacts with the solvent. The proton is very 
deshielded in both DMSO and in the mixed solvent system, indicating that the DMSO is 
acting as a hydrogen-bond acceptor to the solvent-exposed proton. As the temperature is 
increased in the mixed solvent system, the H-bonding interaction is interrupted, the 
proton becomes more shielded, and therefore, resonates at a higher field. 
The opposite case can be made for the Asp NH. This proton has associated with it a 
very small negative temperature coefficient (-0.8 x 10.3 ppm, as measured in the mixed 
solvent system). signifying intramolecular H-bonding. Although no change in the 
chemical shift is noted with the Asp NH as the temperature increases, the corresponding 
peak does seem to broaden quite dramatically compared to the other amide protons, as 
seen in Figure 30. A possible explanation for the observed temperature-dependent 
broadening is that the NH proton begins exchanging more rapidly with its H-bond 
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acceptor as heat is added to the system. It is unclear whether the H-bond acceptor is a 
transannular carbonyl or perhaps the carbonyl of its own side chain. 
Based on their corresponding temperature coefficients, the remaining three amide 
protons, Phe, Gly, and 3-AMB, seem to interact with the solvent. The 3-
aminomethylbenzoic acid aromatic proton a (Figure 1) signal also displays a significant 
upfield shift upon the addition of water, showing that the residue is highly responsive to 
solvent, probably due to H-bonding. The Phe and Gly residues seemed to be equally 
affected by temperature with coefficients of -4.2 x 10-3 and -4.0 x 10-3, respectively. 
4. Further Discussion of Aspartic Acid 
The most puzzling observation from the two studies of the monomeric peptide species 
was the very weak signals of the Asp residue in 100% DMSO. It can be postulated that 
perhaps the Asp residue was interconverting between two conformers in the DMSO 
solvent at such a rate that the signals were broadened. A salt bridge between the arginine 
and aspartate residues could possibly affect the rate of interconversion. If the Asp NH is 
indeed the signal observed at 7.8 ppm in 100% DMSO, it is fairly shielded, indicating 
that it is not interacting with solvent. 
The other potential explanation for such signal broadening would be rapid exchange 
with an H-bond acceptor (other than DMSO). Although it would seem possible for the 
Asp NH to undergo such exchange, the aliphatic protons most likely would not. The 
aliphatic regions of the TOCSY and COSY show the same diminished signal intensity as 
seen in the amide region. 
When water was added, the Asp amide and aliphatic signals became very apparent. 
The addition of water would most likely disrupt any salt bridge and allow the Asp residue 
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to become involved in an intramolecular H-bond. Most likely this H-bond would be 
between the aspartate NH and its carboxylate side chain. The Asp NH signal clearly 
moved downfield compared to the 100% DMSO system, signifying a more deshielded 
environment, perhaps from a strong H-bonding interaction. 
A compari son of the structures generated in the two solvent systems, both based on 
the NH-CuH dihedral angles of Arg and Phe, reveals that a rather dramatic 





The Phe and Arg residues undergo rotation about the NH-Ca bond in the presence of 
water, placing their respective side chains in significantly different orientations in space. 
Perhaps the change in proximity of the Phe aromatic ring to the 3AMB ring has an effect 
on the chemical shift of the aromatic proton a. The difference in the position of the Arg 
side chain in the two solvent systems may account for the observed shift of the Asp NH 
proton, possibly allowing an intramolecular H-bonding interaction to take place in the 
presence of water. In both structures, it appears that the backbone amide proton of Arg 
would be solvent accessible and, therefore, it would be possible for hydrogen bonding 
interactions to take place between that proton and the solvent. 
C. Structural Assessment of Peptide Plb: a cyclic peptide dimer 
Unlike the monomeric peptide species PIa, head-to-tail cyclic peptide dimer Plb 
gives five strong backbone amide signals in 100% DMSO (Figure 32). From this 
observation, several conclusions can be drawn about the structure of Plb in solution. 
Most obvious of these conclusions is that the dimeric conformation is symmetrical in 
nature. If the dimer were asymmetric, all ten backbone amide protons would have 
distinct chemical shifts. Since the Asp residue appears to be involved in an 
intramolecular interaction, as the Asp NH protons resonates downfield at 8.53 ppm and is 
intense, it is reasonable to assume that no salt bridges are formed in the larger molecule. 
Also worth noting, is that the 3-AMB aromatic proton a (Figure 1) is upfield at 87.65, as 
observed in the monomer in DMSO/water. The chemical shifts of Plb are summarized 
in Table 5. 
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Figure 32: I H NMR spectrum of P I b. All five residues appear clearly in 100% DMSO-d6 . 
residue HN' H ' H6' H ' Other 
• 
• , 
Arg 8.53 4.3 1 1.50 1.78 H,: 3.04 
£NH: 7.66 
Gly 8.28 3.72/4.23 
Asp 8. 10 4.46 2.39 
I)-Phe 8. 18 4.40 2.89/3. 14 aromatic: 7.20 
7.3 1 
3-AMB 8.46 3.65/4.49 aromatic: 7.28 
7.62 
7.68 
Table S: Prolon chemical shifts of di meric peptide PI b. 
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IV. SUMMARY 
Seven novel head-to-tail cyclic peptides, all containing the Arg-Gly-Asp 
pharmacophore, were synthesized, purified and characterized. Linkers of varying 
composition and flexibility were incorporated into the peptides. The peptide containing 
4-aminomethylbenzoic acid was unattainable as a cyclic molecule as the rigid, linear 4-
AMB residue did not lend itself well to ring closure. However, inclusion of the bent 3-
AMB molecule did allow for cyclization. It was discovered that the ring-closing step 
with only four residues was unsuccessful, most likely due to torsional strain. Such strain 
was relieved with the addition of another residue. In all but one of the peptides, this fifth 
residue was chosen to be phenylalanine. It was also found that a "D" configuration at the 
fifth position rather than a "L" seemed to be preferred for ring closing, most likely due to 
steric interactions that are lessened during ring closure with a D-amino acid. 
The monomeric cyclic peptide Pta was chosen for structural evaluation using nuclear 
magnetic resonance (NMR) spectroscopy in both 100% DMSO-d6 and a mixed solvent 
system composed of DMSO-d6 : H20 (2: 1). The most puzzling observation from the two 
studies of the monomeric peptide species was the very weak signals of the Asp residue in 
100% DMSO. When water was added, the Asp amide and aliphatic signals became very 
apparent. 
The amide proton chemical shifts in the mixed solvent system were found to display 
temperature-dependence. From the large negative temperature coefficient measured for 
the Arg NH, it is apparent that this proton interacts with the solvent. The Asp amide 
proton, on the other hand, has associated with it a very small negative temperature 
coefficient, signifying intramolecular H-bonding. The Asp NH peak seemed to broaden 
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quite dramatically compared to the other amide protons as heat was added to the system, 
possibly because the NH proton begins exchanging more rapidly with its H-bond 
acceptor. 
By calculating the dihedral angles of the NH-CuH from the J-coupling constants, two 
structural constraints could be placed on the molecule and a model structure generated for 
the peptide in both solvent systems. A comparison of the structures generated in the two 
solvent systems reveals that a rather dramatic conformational change takes place when 
water is added to the system. The difference in the position of the Arg side chain in the 
two solvent systems may account for the observed shift of the Asp NH proton, possibly 
allowing an intramolecular H-bonding interaction to take place in the presence of water. 
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CHAPTER 2 
TARGETING DRUGS TO BONE 
I. BACKGROUND 
A. Pathophysiology and Pharmacological Treatment of Bone Disorders 
Healthy bone is a dynamic tissue, constantly being remodeled via catabolic and 
anabolic processes. Normally bone remodeling is balanced and maintains bone strength. 
Highly specialized cells control the remodeling process: osteoblasts deposit new bone 
tissue, while osteoclasts resorb the tissue. Osteoblasts secrete an extracellular 
proteinaceous matrix, mainly composed of collagen. The matrix becomes mineralized by 
hydroxyapatite (CalO(P04)6(OHh). Two-thirds of the mineral mass in the human body is 
in the bone tissue (Siconolfi, et aI., 1998). 
Diseases of the bone can disrupt the balance of bone formation and resorption. 
Osteoporosis is a disease in which bone resorption outpaces bone formation, causing 
nearly l.3 million bone fractures each year (Hirabayashi and Fujisaki, 2003). One factor 
contributing to the development of osteoporosis in post-menopausal women is a marked 
decrease in estrogen levels. Low estrogen levels have been linked to an increase in 
osteoclast formation, leading to higher rates of bone resorption, and hence, lower bone 
density (Lindsay, et aI, 1976). 
Bone cancer is a disease that affects the tissue by a different mechanism. Malignant 
tumors of the bone result from aggressive, invasive cell growth and destroy normal bone 
tissue. These cells can originate from the bone itself (primary tumor) or from metastasis 
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of cells from soft tissues (secondary tumor). Primary bone tumors are far less common 
than secondary tumors, accounting for only about 0.2% of all cancers (American Cancer 
Society, 2008). 
B. Treatment of Bone Diseases 
Most current medications for treating bone diseases are delivered systemically and, 
therefore, can have adverse effects (Hirabayashi & Fujisaki, 2003). One of the most 
widely publicized examples of a treatment that has the potential for undesired side effects 
is hormone-replacement therapy (HRT). Hormone-replacement therapy raises estrogen 
levels and prevents further bone loss. The major drawback of HRT is that higher 
concentrations of estrogen are associated with an increased risk of cancer of the female 
reproductive tissues (Colditz, et aI, 1995; Schairer, et aI, 2000; Persson, et aI, 1999; 
Smith, Prentice, Thompson, & Hermann, 1975; Ziel & Finkle, 1975; Rodriguez, et aI, 
2001). 
Other therapies for osteoporosis are available and have drawbacks associated with 
them as well. The bisphosphonates (alendronate, risedronate, ibandronate), can cause 
erosion of the esophageal lining (Sia, Iser, Heng & Chen, 2004). Parathyroid hormone, 
("PTH"; teriparatide) although an anabolic, rather than simply anticatabolic, treatment, 
requires daily injections and cannot be used for more than two years. 
Chemotherapy agents are notorious for the effects they have on rapidly dividing cells, 
such as the hair follicles and the lining of the gastrointestinal tract. The anthracyclines 
(doxombicin, daunorubicin, epirubicin, and idarubicin), although highly potent and 
useful against cancer cells, can also affect the musculature of the heart. The 
cardiotoxicity of the anthracyclines can be partially attributed to the formation of free 
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radicals and subsequent free radical lipid peroxidation (SaUan & Clavell, 1984; Floyd, et 
al,2005). 
C. Designing "Smarter" Molecules 
A challenge facing the pharmaceutical industry is making a drug that is not only 
highly effective, but also highly specific in its biological action. When a molecule is 
selected as a potential drug candidate, it must be highly effective at the target tissue or 
organ, while having minimal effects on other tissues. The continuing evolution of 
pharmacology and medicinal chemistry has allowed for considerable progress in the 
development of precise and effective drug action. As the inner workings of biological 
systems are elucidated, opportunities to utilize biomolecules as drug targets become more 
abundant and more specific. Sometimes the biomolecules themselves can be developed 
into therapeutic entities. 
A commonly used strategy for designing molecules with specific pharmacological 
properties involves exploiting the natural biological activity of a known ligand, antigen, 
or substrate to achieve selective binding. For instance, the well-known chemotherapeutic 
agent tamoxifen, used for the treatment of breast cancer, competes with estrogen for 
binding to the estrogen receptor in the breast tissue and tumors. By "blocking" the 
receptor from binding with estrogen, tamoxifen inhibits the growth of estrogen-dependent 
tumor cells and eventually leads to cell death (Jordan, 1993). 
Besides the teeth, bone is the only tissue in the human body that is mineralized by 
hydroxyapatite. Unlike teeth, bone is also highly vascularized, so it can interact with so-
called "hone-seeking" substances (Stepensky, Kleinberg, & Hoffman, 2003). Hence, 
62 
molecules that have an affinity for hydroxyapatite can be utilized to act as "drug carriers" 
that can deliver medicinal agents in a tissue-specific manner. 
D. Chemicals that Bind to Hydroxyapatite 
Some compounds and elements have a natural affinity for bone due to its high 
composition of hydroxyapatite. Stepensky, Kleinberg, and Hoffman (2003) have written 
about the binding properties of some of the substances that bind to bone, including 
fluoride, lead, bisphosphonates, tetracycline, and radioactive agents. Although the 
pharmacokinetics and pharmacodynamics of so-called "bone-seeking" agents may vary, a 
consistent property of these materials is that they are very slowly released from the bone 
tissue once bound. 
Of the drugs currently on the market for the treatment of osteoporosis, bisphosphonates 
are the only compounds that specifically target bone. Bisphosphonates are analogues of 
pyrophosphates that contain a carbon atom instead of an oxygen atom linking two 
phosphonic acids. The deprotonated bisphosphonic acid form of the molecules acts as 
the bone-targeting entity (Zhang, Gangal, and Uludag, 2007). The main drawbacks of 
bisphosphonates and their conjugates as drugs are their long biological half-lives (several 
months to years) and poor oral availability (less than 1 %) (Stepensky, Kleinberg, & 
Hoffman, 2003). The design and development of novel hydroxyapatite-binding 
molecules to use for targeting drugs to bone is, therefore, a worthwhile venture in 
pharmaceutical research. 
E. Tetracycline as a "Bone-Seeking" Molecule 
Tetracycline, first prepared by catalytic hydrogenolysis of aureomycin in 1953 
(Boothe), is noted to be a potent antimicrobial agent. The fact that it also binds to bone 
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has been well established (Skinner, 1975; Myers, 1968). During bone formation, 
tetracycline binds tightly to calcium and it has a terminal half-life on the order of weeks, 
although most of a dose is mostly eliminated from the body within one week, with 3-6% 
remaining in the skeleton (Stepensky, Kleinberg, & Hoffman, 2003). 
Infrared spectroscopic studies of tetracycline adsorbed to hydroxyapatite indicate that 
the "A" ring of the molecule (see Figure 1) is involved in complexation (Myers, Tochon-
Danguy, and Baud, 1983). Significant shifts in the frequencies of the C2 amide bond 
vibrations (C=O and NH2) were observed in adsorbed versus free tetracycline. The data 
also suggested that the two oxygen atoms adjacent to the C2 amide (those at carbons 1 
and 3) are equivalent, with only one frequency observed for both carbonyls at 1615 cm- I . 
This finding is consistent with the crystal data. The amide bond at C2 and the flanking 
carbonyl groups at C 1 and C3 are essential for calcium binding (Albert, 1979). 
OH o OH o o 
Figure 1: Tetracycline 
F. Bone-Targeted Drug Conjugates 
Although no bone-specific drug conjugates are presently available for patient use, a 
good deal of research has been performed on developing such entities over the past 
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several decades. One of the most widely studied classes of molecules for making bone-
targeted pharmaceuticals has been the bisphosphonates. While bisphosphonates 
themselves act as bone resorption inhibitors, they can also be exploited as bone-targeted 
carriers for other drugs. Some of the bisphosphonate conjugates in preclinical trials (as 
of 2003) are three agents for the treatment of osteoporosis, three bone cancer drugs, a 
bone-targeted antibiotic, and an osteoarthritis therapy (see review article Hirabiyashi and 
Fujisaki,2003). An oligopeptide composed of six aspartic acid residues was conjugated 
to estradiol and found to preferentially bind to bone (Kasugai, et aI, 2000). Tetracycline 
has been used as a bone-specific carrier for a carbonic anhydrase inhibitor (Pierce and 
Waite, 1987) and for estradiol (Orme and Labroo, 1994). 
G. Development of a Novel Bone-Targeting Agent 
The A ring of tetracycline is known to be one of the calcium binding domains of the 
molecule. Prior work in this laboratory was focused on developing a novel bone-
targeting agent (BTA) modeled on the structure of this A ring. The motivation for 
constructing a new BT A instead of using the entire tetracycline molecule is three-fold. 
One, because bones are surrounded by a highly selective cell lining, large molecules 
cannot easily access the surface of the bone (Hirabiyashi and Fujisaki, 2003). Secondly, 
tetracycline is in fact an antibiotic drug and could act as such, even when conjugated, 
leading to unwanted side effects. Lastly, from a synthetic standpoint, the A ring of 
tetracycline is a much more practical choice as a chemical synthesis precursor than is the 
entire tetracycline molecule. Because of the number of functional groups, making drug 
conjugates of tetracycline is much more likely to result in unwanted synthetic products 
and would require selective protection/deprotection schemes. 
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The work described on pages 67 to 71 is presented in the dissertation of Dr. Jason 
Neale (2002). Structure-activity relationship (SAR) studies were first carried out on three 
series of bone-targeting molecules (see Figure 2). All three of the bone-targeting entities 
used in the study contained the crucial tricarbonyl moiety mentioned in section E. To 
rapidly check for calcium binding properties, the three potential BTAs were subjected to 
a hydroxyapatite-binding assay. The results from these experiments indicated that the 
Series III compounds had the highest affinity for hydroxyapatite, binding nearly 50% as 
well as tetracycline. The compounds from this series also exhibited no apparent adverse 
effects in vivo. Thus, Series III was chosen for further investigation. 
H. Synthesis and Evaluation of a Series of Bone-Targeted Estrogens 
]n order to further assess the bone-targeting properties of the Series III BT As, a new 
line of BTA-estrogen conjugates were synthesized (see Figure 3). The conjugates were 
composed of four regions: a bone-targeting domain, an estrogenic domain, a spacer ("S") 
between the two domains, and the linkage ("L") connecting the estrogenic domain to the 
spacer. Among these regions, only the estrogenic domain was held constant and was 
derived from 17 -~-estradiol. The linkage at C 17 of estradiol, the length of the spacer 
between the BT A and the estrogenic domain, and the C6 substituent of the BT A were 
varied. The conjugates were all linked via an amide bond at the bone-targeted end of the 
molecule. 
Changing the C 17 linkage from an ester to an ether to a ureido bond altered the 
susceptibility of the bond to hydrolysis. The spacer in between the BTA and estradiol 
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Dring C ring B ring A ring 
Tetracycline LI _____ -----l 
[y0H 
ylyNH2 NH2 
o 0 OR o OR o 
Series I Series II Series III 
Figure 2: Three series of molecules based on the A ring of tetracycline. The tricarbonyl 
region of carbons 1-3 has been shown to be essential for calcium binding. R = CH3, Bz, or H. 
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Estrogenic domain Series III bone-targeting agent 
Compound Estrogenic "L" "S" R 
domain linkage spacer 
BTE2-Al 17~-estradiol Ester -(CH2h- -H 
BTE2-A2 17p-estradiol Ester -(CH2h- -CH3 
BTE2-B2 17p-estradiol Ester -(CH2)4- -CH3 
BTE2-C2 17p-estradiol ------- -------- -CH3 
BTE2-Dl 17~-estradiol Ether -(CH2h- -H 
BTE2-D2 17~-estradiol Ether -(CH2h- -CH3 
BTE2-D3 17~-estradiol Ether -(CH2h- -benzyl 
BTE2-E2 17~-estradiol Ureido -(CH2h- -CH3 
Figure 3: Structure-activity relationship variables of bone-targeted estrogens. 
domains was varied from zero to two to four methylene groups to evaluate the effects on 
hydroxyapatite affinity, hydrolytic susceptibility, and, possibly, estrogenic properties. 
Incorporating different substituents at the C6 position diversified the bone-targeted 
portion of the molecule. After modifying the BT A to include a methoxyl, benzyloxyl, or 
hydroxyl substituent at the C6 position, changes in bone-affinity could be observed. 
The conjugates were first screened via a hydroxyapaptite-binding assay. The affinity 
of the compounds for HA was compared to that of tetracycline. It was discovered that 
the compounds containing a BTA with a methoxyl or benzyloxyl group at C6 bound to 
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HA at significantly higher level (150-200% better) than tetracycline (see Figure 4). It 
was found that conjugating the BTAs to 17 -~-estradiol improved the affinity for HA 
considerably compared to the BTAs alone. 
Since the main disadvantage associated with current hormone-replacement therapy is 
the dual estrogenic effects on the bone and the uterus, the conjugates were tested in vivo 
for improvements in tissue selectivity. As anticipated, estradiol itself was found to have 
virtually no selectivity between the two tissues, with a ratio of femur to uterus stimulation 
of 0.90. In vivo studies of the bone-targeted conjugates revealed that three of the bone-
targeted estradiols, BTE2-Al, BTE2-D2, and BTE2-D3 (see Figure 3 for structures), had 
the highest ratios of femur: uterine tissue selectivity, at ratios of 3.00,3.34, and 2.43, 
respectively. 
Compound BTE2-Al was found to be active when administered orally. The doses 
necessary for bone mass preservation, however, exceeded those necessary when 
subcutaneous administration was used. These results indicated that the conjugate might 
have been incompletely absorbed, possibly due to hydrolysis of the ester linkage during 
metabolism. 
One other noteworthy observation from the in vivo assessment of the bone-targeted 
conjugates is that two of the most highly selective compounds, BTE2-D2 and BTE2-D3, 
were discovered not only to preserve, but also to increase bone density. BTE2-D2 
preserved bone density at a level of 250% compared to sham animals; BTE2-D3 
preserved it at 300%. These increases in bone density signify that the bone-targeted 
estradiol conjugates may be anabolic in nature, helping to build bone tissue, rather than 
simply slowing resorption. To date, the most widely prescribed pharmaceutical available 
69 
for osteoporosis treatment that has anabolic properties is parathyroid hormone (marketed 
as Forteo®). Although parathyroid hormone and related compounds build bone, they are 
















__ II I 
Figure 4: Comparative hydroxyapatite binding of bone-targeted estrogens. Tetracycline is defined as 
having a relative binding index of 100. 
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II. GOALS OF THIS PROJECT 
A. Develop a "Shelf-Stable" Bone-Targeting Entity 
In order to fully realize the potential of the newly discovered line of bone-targeting 
agents, it became evident that "uni versal" BT A would be invaluable. In the previous 
synthetic work, the spacer was attached to 17-~-estradiol before conjugation to the BT A. 
This approach worked well when only bone-targeted estrogens were being studied, but if 
other drug conjugates were to be made, a more rational approach would be to attach the 
spacer to the BT A. With such a compound in hand, a seemingly endless number of drugs 
could be targeted to bone tissue by simply attaching them to the BTA-spacer molecule. 
Hence, one of the goals of this project was to synthesize a number of the BTA-spacer 
compounds and to assess their use and versatility as "shelf' reagents for making bone-
targeted drugs. 
Previous patented work was done attempting to make such a bone-targeted compound. 
A succinic acid linker arm was attached to the bone-targeting agents via the amino 
position. Unfortunately, further couplings with these linked compounds were 
unsuccessful. It was speculated that the succinic linker, rather than reacting with the 
desired molecule to make a bone-targeted conjugate, underwent an intramolecular 
cyc\ization (see Figure 5). The next generation of linkers will be carefully selected to 
avoid such a problem. Given that the estradiol conjugates of BTAs "D2" and "D3" (see 
Figure 6) were found to be the most biologically active and tissue selective compounds 
from the first series of studies, the universal BTA will be developed from one of these 




0 0 ? OH 
• .. 
NH2 NH2 
OR 0 OR 0 
Figure 5: Postulated intramolecular cyc\ization of previous bone-targeting agents with linker arms. 
OR 0 
Figure 6: Bone-targeting agents "D2" (1: R = CH]) and "Dr (2: R = Bz) were found to result in the 
most potent and selective estradiol conjugates 
B. Further Investigate the Effect of the Spacer ("S") on Oral Activity 
A secondary goal of the project was to determine if variations of the spacer had a 
substantial effect on the oral bioavailability of the bone-targeted estrogens. As discussed 
in Part I Section H, the oral availability of the BT A-estradiol compounds may have been 
limited by the adsorption of the molecules into the bone tissue. One strategy for possibly 
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enhancing cell uptake of the bone-targeted species is to make the spacer more 
amphiphilic. 
The first series of bone-targeted estrogens contained hydrophobic spacers, composed 
mostly of methylene groups. The next series of compounds in this study will utilize 
spacers of varied lengths and varied compositions. The bifunctional linker 8-amino-3,6-
dioxaoctanoic acid ("mini-PEG") and the longer version ll-amino-3,6,9-
trioxaundecanoic acid, because of their hydrophilic nature and flexibility, were chosen to 
be the spacers incorporated into the new series of bone-targeted estrogens. 
C. Design and Synthesize New Bone-Targeted Conjugates 
Because of its structural similarity to 17~-estradiol and ability to bind to the estrogen 
receptor, genistein, an isoflavone isolated from soybeans, falls into a class of compounds 
known as "phytoestrogens." Genistein actually exists almost exclusively as the ~-










# hydrolysis DOH 0 
-_. I~ I 
HO #'-.......0 
genistein 
Figure 7: Genistin is hydrolyzed by a ~-glucosidase during digestion to yield genistein. 
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Genistein has been found to have an anabolic effect on bone tissue and to inhibit bone 
resorption (Yamaguchi, 2002). However, unlike hormone-replacement therapy, genistein 
appears to be selective for bone tissue and bone marrow, not having notable effects on 
reproductive tissues (Ishimi, et ai, 1999; Wang, et aI200S). Hence, to further reduce the 
potential adverse estrogenic effects, a bone-targeted genistein compound became an 
attractive target for our current project. 
In addition to bone-targeted estrogens/estrogen mimics, other molecules can be linked 
to the BT compounds. Doxorubicin, an anticancer drug, has been conjugated to a 
bisphosponate via a polymeric linker and was found to retain affinity for hydroxyapatite 
(Hruby, et aI, 2006). Because of the potential for a targeted treatment for bone 
metastases, bone-targeted conjugates of doxorubicin are of interest for this project. 
Fluorescein isothiocyanate (FITC) was conjugated to a bisphosphonate and a small, 
acidic peptide known to have bone-seeking properties (Wang, et aI, 2003). The 
fluorescence of the conjugates was studied in vitro and in vivo and both compounds were 
found to bind to bone. Similarly, we would like to conjugate our BTAs to a fluorescent 
marker to be able to study the tissue distribution in vivo. 
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III. EXPERIMENTAL 
General Methods. Benzotriazole-1-yl-oxy-tris-( dimethylamino) phosphonium 
hexafluorophosphate (BOP) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) were purchased from Advanced ChemTech, 1-
hydroxybenzotriazole (HOBt) from Quantum Technologies, and 9-
fluorenylmethoxycarbonyl (Fmoc-) and tert-butyloxycarbonyl-miniPEGs (Boc-
miniPEGs) from Peptides International. 3-amino-2-hydroxy-6-methoxybenzamide and 3-
amino-6-benzyloxy-2-hydroxybenzamide hydrochloride were purchased in bulk from 
Ricerca Biosciences, Concord, OH. All solvents and other reagents were purchased from 
either Fisher Scientific or Sigma-Aldrich. Reagent grade solvents were either purchased 
and used immediately or were freshly distilled before use. Varian Bond-Elut cartridges 
packed with C 18 bound to silica gel were employed for reverse-phase chromatographic 
separation. 
High-resolution mass spectrometry was performed by Dr. Jian Cai in the Department 
of Pharmacology and Toxicology at the University of Louisville School of Medicine. 
The instrument used was a Q-TOF API US from Waters. The samples were dissolved in 
50% ACN/O.1 % formic acid and analyzed by ESI in positive ion mode. The capillary 
voltage was 3.25 kV and the mass resolution was 8500. 
NMR experiments were performed on a Varian INOVA 500 MHz spectrometer. 
Fluorescence spectroscopy was performed by Dr. Daxin Tang in the Department of 
Ophthalmology at the University of Louisville on an ISS PC1 photon counting 
fluorimeter. 
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1. Synthesis of Bone-Targeting Agent 1: 3-amino-2-hydroxy-6-methoxybenzamide 
(Scheme 1) 
a. Esterification of 2, 6-dihydroxybenzoic acid (DHBA): methyI2,6-
dihydroxybenzoate (3) 
DHBA (10.00 g, 65 mmol), potassium bicarbonate (6.51 g, 65 mmol), and 18-crown-6 
ether (90 mg, 0.33mmol) were mixed in dry acetone (100 mL). The solution stirred at 
room temperature for 10 minutes before dimethylsulfate (7.00 mL, 72 mmol) was added. 
The reaction stirred for 18 hours at room temperature before being evaporated 
under vacuum to give a solid. The solid was taken up in CHCh (50 mL), stirred for 5 
minutes, and then treated with solid NaHC03 and filtered. The resulting filtrate was 
washed with water 2X and brine 2X. The organic layer was dried over Na2S04, filtered, 
and evaporated to dryness to give an oil. A precipitate formed upon trituration. The 
mixture was recrystallized from EtOH/water to give white solid 3, collected by vacuum 
filtration. Yield: 8.24 g, 75%. lH (500 MHz, DMSO-d6): 83.78, s, 3H, OCH3; 86.34, d, 
J 8.05 Hz, 2H, C3 HI C5 H; 87.09, t, J 8.17 Hz, IH, C4 H. 
b. Aminolysis of 3: 2,6-dihydroxybenzamide (4) 
Product 3 (3.00 g, 18 mmol) was dissolved in 75 mL methanol (freshly distilled from Mg 
turnings). The solution was cooled in an ice bath and anhydrous ammonia was bubbled 
through until approximately 5 g had transferred. The reaction was kept in an ice bath and 
stirred. After 5 hours, the green solution was evaporated to yield a green solid. The solid 
was dissolved in hot MeOH and treated with charcoal. After filtering, the filtrate was 
cooled to 4°C to give a sticky solid. The solid was dissolved in hot ethanol and filtered 
through Celite. After cooling, white solid 4 was collected. Yield: 1.64 g, 55%. lH (500 
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MHz, DMSO-d6): 86.34, d, J 8.0S Hz, 2H, C3 HI CS H; 87.1S, t, J 8.30 Hz, IH, C4 H; 
88.0S, s, IH, Cl amide H; 88.33, s, IH, Cl amide H; 812.63, s, 2H, phenolic H. 
c. Methylation of 4: 2-hydroxy-6-methoxybenzamide (5) 
Product 4 (2.6 g, 17 mmol) was dissolved in dry acetone (100 mL) in a 3-neck round-
bottom flask. To the solution was added K2C03 (4.67 g, 34 mmol) and the solution was 
stirred for 30 minutes at room temperature under nitrogen. Dimethylsulfate (1.9 mL, 20 
mmol) was added dropwise to the stirring solution over a period of 10 minutes. The 
solution was brought to reflux and held there for 18 hours. A significant amount of white 
precipitate was noted. The flask was allowed to cool to room temperature and then in an 
ice bath for 30 minutes. The solid was filtered off and washed with acetone 3X. The 
filtrate was evaporated to give white solid 5. Yield: 1.76 g, 62%. IH (SOO MHz, 
DMSO-d6): 83.88, s, 3H, C6 OCH3 ; 86.48, d, J 8.30 Hz, IH, C3 H ; 86.53, d, J 8.0S Hz, 
IH, CS H; 87.32, t, J 8.42 Hz, 1 H, C4 H; 88.12, s, IH, Cl amide H; 88.18, s, IH, Cl 
amide H. 
d. Nitration of 5: 2-hydroxy-6-methoxy-3-nitrobenzamide (6) 
Product 5 (3.00 g, 18 mmol) was dissolved in ISO mL of glacial acetic acid. The solution 
was cooled in an ice bath and concentrated nitric acid (12 mL) was added. The reaction 
was stirred at room temperature for 18 hours. The reaction was quenched with cold water 
and the product, 6, was collected via vacuum filtration. Yield: 56%. IH (SOO MHz, 
DMSO-d6): 84.00, s, 3H, C6 OCH3; 86.7S, d, J 9.39 Hz, IH, CS H; 88.1S, d, J 9.39 Hz, 
IH, C4 H; 88.34, s, IH, Cl amide H; 88.47, s, IH, Cl amide H. 
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e. Reduction of 6: 3-amino-2-hydroxy-6-methoxybenzamide (1) 
Product 6 (1.00 g, 5 mmol) was taken up in 100 mL of MeOH along with Pd-C (5% Pd; 
600 mg). The mixture was brought to reflux and hydrazine-hydrate (N2H4 50-60 %, 1.6 
mL) was added via a dropping funnel. The mixture was allowed to reflux overnight. The 
reaction mixture was filtered through Celite and the filtrate was concentrated in vacuo. 
The resulting solid was dissolved in hot water and hot gravity filtration was performed. 
Upon cooling, fine brown crystals of 1 formed. Yield: 610 mg, 67%. IH (500 MHz, 
DMSO-d6): 83.79, s, 3H, C6 OCH3; 86.33, d, J 8.54 Hz, 1H, C5 H; 86.73, d, J 8.66 Hz, 
1H, C4 H; 88.08, s, 1H, C1 amide H; 88.21, s, 1H, C1 amide H. 
(CHJlzS04 ~H 
KHCOJ I" 
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2. Coupling of Fmoe-mini-PEG to Bone-Targeting Agent 1: (9H-fluoren-9-yl)methyl 
2-(2-(2-(3 -carbamoy 1-2-h ydrox y-4-methox yphen ylamino )-2-
oxoethoxy)ethoxy)ethylcarbamate (7, Scheme 2) 
Fmoc-8-amino-3, 6-dioxaoctanoic acid ("Fmoc-mini-PEG", 2.5 g, 6.5 mmol) along 
with hydroxybenzatriazole (HOBt; 0.88 g, 6.5 mmol), benzotriazole-1-yl-oxy-tris-
(dimethylamino)-phosphonium hexafluorophosphate (BOP; 2.87 g, 6.5 mmol), and 
diisopropylethylamine (DIEA; 1.13 mL, 6.5 mmol) were dissolved in dimethylformamide 
(DMF; 20 mL). In a separate flask, bone-targeting agent 3-amino-2-hydroxy-6-
methoxybenzamide (0.89 g, 4.9 mmol) was dissolved in 20 mL DMF. After ~3 minutes, 
the two solutions were mixed together and stirred at room temperature for 24 hours. The 
DMF was removed under vacuum and crude product appeared as a brown oil. 
The oily product was taken up in ethyl acetate and washed with brine 2X, 5% HCl2X, 
and saturated NaHC03 2X, then dried over sodium sulfate. It was then concentrated via 
rotary evaporation and a sticky brown oil resulted. When this oil was dissolved in 
methanol and triturated, a brownish-white solid precipitated out. The mixture sat at 4°C 
for ~ 72 hours and solid product 7 was collected via vacuum filtration. Yield: 1.96 g, 
73%. IH NMR (500 mHz, DMSO-d6): 03.15, m, 2 H, 6' CH2; 03.44, t, J 5.98 Hz, 2 H, 5' 
CH2; 03.60, br s, 2 H, 4' CH2; 03.69, br s, 2 H, 3' CH2; 03.88, s, 3 H, C6 OCH3; 04.09, s, 
2 H, 2' CH2; 04.19, q, J 6.59 Hz, 1 H, 9' CH; 04.27, d, J 6.40 Hz, 2 H, 8' CH2; 06.54, d, J 
8.97 Hz, 1 H, C5 H; 07.31, m, 3 H, C14' H/C6 amide H; 07.40, m, 2 H, C12' H; 07.67, d, 
J 7.87 Hz, 2 H, C13' H; 07.88, d, J 7.32 Hz, Cll' H; 08.18, d, J 8.60 Hz, 1 H, C4 H; 
08.29, s, 1H, C1 amide H; 08.33, s, 1 H, C1 amide H; 08.85, s, 1H, C3 amide H. 
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3. Fmoc-Deprotection/Formation of Hel Salt: 2-(2-(2-(3-carbamoyl-2-hydroxy-4-
methoxyphenylamino)-2-oxoethoxy)ethoxy)ethanaminium chloride (8, Scheme 3) 
Compound 7 (3.5 g, 6 mmol) was dissolved in 20% piperidine in DMF and stirred for 20 
minutes. At that time, the solvent was removed in vacuo and fresh piperidine solution 
was added to repeat the reaction. Altogether, the deprotection was performed three times. 
After the third solvent removal, a solid product appeared and diethyl ether was added. 
The mixture was acidified with 7 N HCl in methanol and decanted. A light brown 
precipitate, 8, was collected via vacuum filtration. Yield: 1.9(~ g, 90%. IH (500 mHz, 
DMSO-d6): 02.96, t, 2 H, 6' CH2; 03.65, m, 4 H, 4' /5' CH2; 03.73, m, 2 H, 3' CH3; 
03.89, s, 3 H, C6 OCH3; 04.12, 2 H, 2' CH2; 06.56, d, J 8.91 Hz, 1 H, C5 H; 08.17, d, J 
9.15 Hz, 1 H, C4 H; 08.30, s, 1 H, Cl amide H; 08.35, s, 1 H, Cl amide H; 08.87, s, 1 H, 
C3 amide H. DC (500 mHz, DMSO-d6): 039.16, C6'; 056.86., C6 -OCH3; 067.43, C5'; 
070.17, C4'; 070.77, C3'; 070.97, C2'; 0100.96, C5; 0156.70, qC; 0103.21, qC; 8120.85, 
C4; 8124.95, qC; 8154.94, qC; 8155.47, qC; 8168.22, qC; 8172.54, qc. Mass calculated: 
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4. a. Coupling of Bone-Targeting Agent to Fmoc-ll-Amino-3,6,9-Trioxaundecanoic 
Acid: (9H-fluoren-9-yl)methyl 2-(2-(2-(2-(3-carbamoyl-2-hydroxy-4-
ethoxyphenylamino )-2-oxoethoxy)ethoxy)ethoxy)ethy1carbamate b. Fmoc-
Deprotection/Formation of HCI Salt: 2-(2-(2-(2-(3-carbamoyl-2-hydroxy-4-
methoxyphenylamino)-2-oxoethoxy)ethoxy)ethoxy)ethanaminium chloride 
(9, Scheme 4) 
Fmoc-ll-amino-3 ,6,9-trioxaundecanoic acid ("Fmoc-mini -PEG-3", from Peptides 
International, Louisville, KY; 5.00 g, 11.6 mmol) was dissolved in 10 mL DCM along 
with DIEA (3 mL, 17.2 mmol). A second solution was made with BOP (5.12 g, 11.6 
mmol), HOBt (1.55 g, 11.6 mmol), and DIEA (2 mL, 11.5 mmol) in DCM (40 mL). The 
two solutions were combined and stirred. Finally, 3-amino-2-hydroxy-6-
methoxybenzamide (2.11 g, 11.6 mmol) was added to the reaction solution and it was 
stirred overnight at room temperature. 
The solution was diluted with 120 mL of EtOAc then washed with brine 2X, 5% HCI 
2X, and saturated sodium bicarbonate 2X. The organic layer was dried over sodium 
sulfate and evaporated to dryness under vacuum to give a brown oil. The oil was taken 
up in 20% piperidine in DMF (20 mL) and stirred. After 10 minutes, a precipitate 
formed. This white solid (BOP reagent) was collected via vacuum filtration and the 
filtrate was concentrated in vacuo. The resulting oil was twice more treated with 20% 
piperidine in DMF for 15 minutes and the solvent removed under vacuum. Finally, a 
brown solid was obtained. Immediately, ether was added to the solid and the mixture 
was acidified with 7N HCI in MeOH. The solvent was removed and once again the 
product was taken up in ether and acidified. The mixture was allowed to sit at 4°C 
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overnight. A light brown precipitate, 9, was collected via suction filtration. Yield: 2.48 
g,53%. 
IH (500 mHz, DMSO-d6): 02.92, q, J 5.49 Hz, 2H, C8' CH2; 03.54-3.60, m, 6H, 5'-7' 
CH2; 03.62, m, 2H, 4' CH2; 03.69, m, 2H, 3' CH2; 03.88, s, 3H, C6 OCH3; 04.10, s, 2H, 
2' CH2; 05.50, br s, 3H, NH/; 06.55, d, J 9.15 Hz, IH, C5 H; 08.17, d, J 8.97 Hz, IH, C4 
H; 08.30, br s, 1 H, Cl amide H; 08.35, br s, IH, Cl amide H; 08.87, br s, IH, C3 amide 
H. BC (500 mHz, DMSO-d6): 039.17, CH2; 056.86, C6 OCH3; 067.33, CH2 ; 070.36, CH2 
(int=3); 070.81, CH2; 071.20, CH2; 0100.97, C5; 0103.19, qC; 0120.87, qC; 0124.85, C4; 
0154.89, qC; 0155.44, qC; 0168.26, qC; 0172.55, qc. Mass calculated: 371.1693; Mass 
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Yield: 2.48 g, 53 % 
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Scheme 4: a. Coupling of bone-targeting agent (2-hydroxy-6-methoxy-3-amino-benzamide) to Fmoc-JJ-

















S. Coupling of Fmoc-mini-PEG to Bone-Targeting Agent 3-amino-6-benzyloxy-2-
hydroxybenzamide hydrochloride: 4-( 1-(9H -fluoren-9- yl)-3-oxo-2, 7,1 0-ttioxa-4-
azadodecanamido)-2-carbamoyl-3-hydroxyphenyl benzoate (10, Scheme 5) 
In a 200 mL round-bottom flask were dissolved Fmoc-mini-PEG (S.OOg, (13 mmol), 
3-amino-6-benzyloxy-2-hydroxybenzamide hydrochloride (from Ricerca Biosciences, 
Concord, OH; 2.9Sg, 10 mmol), HOBt (3.SIg, 26 mmol), BOP (l1.Sg, 26 mmol), and 
DIEA (4.53 mL, 26 mmol), in DMF (70 mL). The homogeneous solution was allowed to 
stir at room temperature overnight. The DMF was removed under vacuum after ~22 
hours to give a dark brown oil. The oil was dissolved in 100 mL EtOAc and washed with 
brine 2X, S% HCI2X, and saturated NaHC03 2X, then dried over sodium sulfate and 
concentrated via rotary evaporation to give a sticky brown residue. The residue was 
taken up in methanol and triturated. An off-white precipitate (10) was collected and 
washed with MeOH via vacuum filtration. Yield:= 4.67g, 70%. 'H (SOO mHz, DMSO-
d6): b3.lS, t, J S.SO Hz, 2H, 6' CH2; b3.44, t, J S.73 Hz, 2 H, S' CH2; b3.S9, br s, 2H, 4' 
CH2; b3.67, br s, 2H, 3' CH2; M.I9, t, J 6.71 Hz, 1 H, C9' H; M.27, d, J 6.83 Hz, 2 H, 2' 
CH2; bS.27, s, 2 H, C6 CH2 (benzyl); b6.64, d, J 8.78 H, I H, CS H; b7.31, m, 3H, C14' 
Hlbenzyl He; b7.36, d, J 7.32 Hz, 1 H, 6' amide H; b7.40, m, 4 H, C12' Hlbenzyl Hb; 
b7.48, d, J 7.20 Hz, 2 H, benzyl Ha; b7.67, d, J 7.20 Hz, 2H, C13' H; b7.87, d, J 7.69 Hz, 
2H, Cl1' H; b8.13 Hz, d, J 4.S2 Hz, IH, C4 H; b8.I9, s, IH, CI amide H; b8.36, s, I H, 
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6. Deprotection of 4IFormation of He} Salt: 2-(2-(2-(4-(benzoyloxy)-3-carbamoyl-2-
hydroxyphenylamino )-2-oxoethoxy)ethoxy)ethanaminium chloride (11, Scheme 6) 
Compound 10 (2.50g, 3.8 mmol) was dissolved and stirred in -20 mL of 20% 
piperidine in DMF for 20 minutes before the solvent was removed under vacuum. The 
piperdine treatment and solvent removal were repeated twice more. After the final 
solvent removal, the mixture was taken up in ether and acidified with 7N HCI in MeOH. 
A white precipitate was collected via filtration, however the solid proved to be the Fmoc 
hydrocarbon. The remaining filtrate was concentrated and taken up in a small amount of 
methanol. It was then allowed to sit in MeOH at 4°C for 48 hours. A solid/oil mixture 
resulted. The mixture was dried under vacuum for 1 hour, taken up in ether, then briefly 
exposed to dry ice-acetone bath and triturated. After some 10 minutes, a light purple 
precipitate was noted. This solid was collected via vacuum filtration and then 
recrystallized from methanol/ether to give off-white solid, 11. Yield: 740 mg, 57% .'H 
(500 mHz, DMSO-d6): b2.94, t, J 5.37 Hz, 2 H, 6' CH2; b3.63, m, 4 H, 4'/5' CH2; b3.71, 
m, 3' CH2,; M.ll, s, 2 H, 2' CH2; b5.29, s, 2 H, benzyl CH2; <>6.65, d, J 9.15 Hz, 1 H, C5 
H; b7.36, d, J 7.20 Hz, 1 H, benzyl He; b7.41, t, J 7.44 Hz, 2 H, benzyl Hb; b7.49, d, J 
7.69 Hz, 2 H, benzyl Ha; b8.l2, d, J 9.03 Hz, 1 H, C4 H; b8.20, s, 1 H, Cl amide H; 
b8.37, s, 1 H, Cl amide H; ()8.88, s, 1 H, C3 amide H. I3C (500 mHz, DMSO-d6): 
b39.18, C6'; b67.61, C5'; b70.16, CH2; b70.78, CH2;b70.98, CH2; b71.08, CH2; b102.63, 
C5; b103.82, qC; b121.09, qC; b124.82, C4; b128.68, benzylic C; b128.99, benzylic Ce; 
b129.36, benzylic C; b136.84, qC; b154.21, qC; b154.90, qC; b168.28, qC; b172.52, qc. 
Mass calculated: 403.1743; Mass found: 403.1738,!1 = -1.30 ppm. 
95 
OBz 0 ~ 20% piperidine in DMF 
OBz 0 
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7. Coupling of ~-estro-O-propanoic acid to 8: 2-hydroxy-3-(2-(2-(2-(3-((l7R)-3-
hydroxy-13-methyl-7 ,8,9,11,12,13,14,15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-
17 -yloxy)propanamido )ethoxy)ethoxy)acetamido )-6-methoxybenzamide (12, Scheme 7) 
In a round-bottom flask were combined the following: 17-~-estro-O-propanoic acid 
(0.48 g, 1.4 mmol), HOBt (0.38 g, 2.8 mmol), BOP (1.24g, 2.8 mmol), and 8 (see scheme 
3; 0.5g, 1.4 mmol). The dry mixture was dissolved in DMF (20 mL) then DIEA (488 
J.lL, 2.8 mmol) was added. The reaction was allowed to stir at room temperature for -48 
hours. 
The reaction solvent was removed under vacuum and the resulting yellow oil was 
taken up in -50 mL ethyl acetate (EtOAc). It was then washed with brine 2X, 5% HCl 
2X, and saturated sodium bicarbonate 2X and dried over sodium sulfate. After gravity 
filtration, the filtrate was condensed via rotary evaporation to yield a sticky oil. Upon 
trituration of the oil in cold methanol, product 12 precipitated out as an off-white solid. 
The product was collected via vacuum filtration. Yield: 510 mg, 56%. IH (500 mHz, 
DMSO-d6): 80.66, s, 3 H, angular methyl; b1.lO, m; b1.16-1.32, m; b1.35, m; b1.55, m; 
b1.73, m; b1.86-1.97, m; b2.04, t; b2.19, d; b2.27, t, J 6.47 Hz, 2H, 8' CH2; b2.68, m, 2 
H; b3.21, q, J 5.61 Hz, 2 H, 6' CH2; b3.44, t, J 5.86 Hz, 2 H, 5' CH2; b3.55, m, 1 H, C9' 
HI; b3.60, m, 2 H, 4' CH2 ; b3.69, m, 2 H, 3' CH2; b3.63, m, 1 H, C9' H2; b3.87, s, 3 H, 
C6 OCH3; M.09, s, 2 H, 2' CH2; b6.42, br s, 1 H, C18' H; b6.49, dd, J1 8.54 Hz, J2 2.20 
Hz, 1 H, C20' H; b6.54, d, J 9.03 Hz, 1 H, C5 H; b7.01, J 8.54 Hz, 1 H, C21' H; b7.81, t, 
J 5.61 Hz, 1 H, C6' amide H; b8.19, d, J 9.03 Hz, 1 H, C4 H; b8.29, s, 1 H, Cl amide H; 
08.33, s, 1 H, Cl amide H; 08.85, s, 1 H, C3 amide H; 08.96, s, 1 H, C19' OH. 13e: 
b12.22, angular CH3; b23.29, CH2; b26.77, CH2; b27.48, CH2 ; b28.25, CH2; b29.80, CH2; 
99 
337.30, CH2 ; 338.04, CH2 ; 339.04, CH2 ; 339.13, CH; b43.47, qC, C26'; b44.03, CH; 
356.80, C6 OCH3; b66.49, CH2; 369.94, CH2 ; 370.05, CH2 ; 370.78, CH2 ; 371.14, CH2; 
388.87, CH; 3100.89, CH; 3103.15, qC; 3113.40, CH;; 3115.59, CH; 3120.92, qC; 
3124.69, CH; 3126.75, CH; 3130.97, qC; 3137.78, qC; 3154.84, qC; 3155.39, qC; 
3155.55, qC; 3168.17, qC; 3171.00, qC; 3172.56, qC. Mass calculated: 653.3312; Mass 
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8. Isolation of BTA-MP3-steroid: 2-hydroxy-3-(l5-((l7R)-3-hydroxy-13-methyl-
7,8,9,11,12, 13, 14,15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-17-ylo xy)-13-oxo-
3,6,9-trioxa-12-azapentadecanamido )-6-methoxybenzamide (13) 
o 
HNJlvO~O~O~NH 10' 
~ OH y---0 
14 } 0 
~ NH2 
13 
Yield: 50 mg, 14.4% 
OH 
The crude estradiol conjugate was formed as described in 6 using 0.5 mmol (348 mg) 
of 8, 17-~-estro-O-propanoic acid (175 mg, 0.5 mmol), HOBt (68 mg, 0.5 mmol), BOP 
(221 mg, 0.5 mmol), and DIEA (131 IJ,L, 0.8 mmol). The product was oily, but after 
sitting in hexane at 4°C for some 8 weeks, a light gray precipitate could be collected via 
vacuum filtration. This solid, 13, was subjected to thin-layer chromatography and 'H 
NMR for characterization. Yield =:: 50 mg, 14.4%. 'H (500 mHz, DMSO-d6): <50.66, s, 
3H, angularCH3; <51.12, m; <51.16-1.33, m; <51.35, m; <51.57, m; <51.74, m; <51.S6-1.99, m; 
<52.05, t; <52.21, m; <52.2S, t, 1 6.22 Hz, 2H, 10' CH2;<52.6S, m; <53.17, m, 2H, S'CH2; 
<53.38, m, 2H, 7' CH2; <53.50, m, 2H, 6' CH2; <53.56, m, 3H, 5' CH2, C11' Hb; <53.62, m, 
3H, 4' CH2, C11' Ha; <53.70, m, 2H, 3' CH2; <53.S7, s, 3H, C6 OCH3; M.OS, s, 2H, 2' 
CH2; M.4I, s, 1H, C21' H; M.4S, dd, 1, S.42 Hz, 12 2.56 Hz, 1H, C23' H; <56.54, d, 1 9.15 
Hz, IH, C5 H; <57.02, m, 1H, C24' H; <57.S2, t, 1 5.12 Hz, 1H, CS' amide H; <5S.1S, d, 1 
9.15 Hz, 1H, C4 H; <5S.29, s, 1H, C1 amide H; <5S.34, s, lH, Cl amide H; ()8.S5, s, lH, 
C3 amide H; ()8.97, s, lH, Cl9' OH. Mass calculated: 697.3574; Mass found: 
































9. Coupling of ~-estro-O-propanoic acid to 11: 6-(benzyloxy)-2-hydroxy-3-(2-(2-( -
(3-« 17R)-3-hydroxy-13-methyl-7 ,8,9,11,12,13,14,15,16, 17-decahydro-6H-
cyc1openta[ a ]phenanthren-17 -ylox y )propanamido )ethox y)ethoxy)acetamido)benzamid 
(14, Scheme 8) 
In a 25 mL round-bottom flask was dissolved 11 (300 mg, 0.7 mmol), ~-estro­
propanoic acid (250 mg, 0.7 mmol), BOP (620 mg, l.4mmol), HOBt (189 mg, 1.4 m 1), 
and DIEA (244 /-11,1.4 mmol) in 15 mL ofDMF. The reaction was allowed to stir at 
room temperature for two days, after which time the solvent was removed under vacu m. 
The resulting oil was taken up in ethyl acetate and washed with brine 2X, 5% HCl 2X, 
and saturated NaHC03 2X. The organic layer was then dried over Na2S04, filtered, a d 
concentrated. The product resulted as an oil. The product was combined with another 
oily product obtained from a previous experiment, then subjected to column 
chromatography (solvent system = EtOAc:Acetone, 9: 1). After the appropriate fractio s 
were pooled and concentrated, sticky gray oil 14 was obtained. Yield: 300 mg, 58%. 
(500 mHz, DMSO-d6): 60.66, s, 3H, angular methyl; 61.09, m; 61.16-1.32, m; 61.35, 
61.55, m; 61.73, m; 61.85-1.96, m; 62.04, t; 62.19, d; 62.28, t, J 6.47 Hz, 2H, 8'CH2; 
62.68, m, 2H; 63.21, q, J 5.61 Hz, 2H, 6' CH2; 63.44, t, J 5.61 Hz, 2H, 5' CIIz; 63.55, , 
1H, C9' HI; 63.60, m, 2H, 4' CH2; 63.63, m, 1 H, C9' H2; 03.69, m, 2H, 3' CH2; M.l 
2' CH2 ; 65.26, s, 2H, C6 OCH2; 66.42, br s, 1 H, C18' H; 66.49, dd, J I 8.67 Hz, J2 1.9 
Hz, IH, C20' H; 66.65, d, J 9.15 Hz, 1H, C5 H; 67.01, d, J 8.54 Hz, 1 H, C21' H; 67.3 , 
d, J 7.44 Hz, lH, He; 67.40, t, J 7.50 Hz, 2H, Hb; 67.47, d, J 7.81 Hz, 2H, Ha; 67.82, t, 
5.37 Hz, IH, C6' amide H; 08.15, d, J 9.l5 Hz, lH, C4 H; b8.18, br S, lH, Cl amide 
68.36, br s, lH, Cl amide H; b8.86, s, lH, C3 amide H; 68.97, 1H, C19' OH. DC (50 
108 
mHz, DMSO-d6): 312.13, angular CH3; 323.30, CH2; 326.78, CH2; 327.50, CH2; 328. 8, 
CH2; 329.81, CH2; 337.33, CH2; 338.05, CH; 339.05, CH; 343.48, C26'; 344.04, CH; 
350.20, CH; 366.51, CH2; 369.95, CH2; 370.05, CH2; 370.79, CH2; 371.13, CH2 (int= ); 
388.89, CH; 3102.57, CH; 3113.41, CH; 3115.60, CH; 3121.17, qC; 3124.54, CH; 
3126.73, CH; 3128.69, CH (int=2); 3129.00, CH; 3129.37, CH (int=2); 3130.97, qC; 
3136.79, qC; 3137.77, qC; 3154.15, qC; 3154.76, qC; 3155.59, qC; 3168.19, qC; 
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Scheme 8: Coupling of ~-estro-O-propanoic acid to 11. 
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10. Coupling of Glutaric Anhydride to 8: 5-(2-(2-(2-(3-carbamoyl-2-hydroxy-4-
methoxyphenylamino )-2-oxoethoxy)ethoxy)ethylamino )-5-oxopentanoic acid (15, 
Scheme 9) 
In a 100 mL round-bottom flask was combined 8 (500 mg, 1.4 mmol), glutaric 
anhydride (155 mg, 1.4 mmol), DIEA (590 111,3.4 mmol) and DMF (40 mL). A 
homogeneous solution formed and it was stirred overnight at room temperature. 
Approximately 20 mL of 50% aq. MeOH was then added to the reaction solution and 't 
was allowed to stir for 30 minutes more. The solvent was removed under vacuum to g've 
a sticky brown solid. When triturated in methanol, off-white precipitate 15 was noted 
and collected via suction filtration. Yield: 495 mg, 83%. lH (500 mHz, DMSO-d6): 
81.68, quintet, J 7.56 Hz, 2H, 9' CH2;82.08, t, J 7.44, 2H, 10' CH2; 82.18, t, J 7.56 Hz 8' 
CH2 ; 83.19, m, 2H, 6' CH2 ; 83.43, t, J 5.61 Hz, 2H, 5' CH2 ; 83.60, m, 2H, 4' CH2; 83. 9, 
m, 2H, 3' CH2; 83.89, s, 3H, C6 OCH3; 84.09, s, 2' CH2; 86.56, d, J 9.03 Hz, IH, C4 
87.83, m, IH, C6' amide H; 88.18, d, J 9.39 Hz, IH, C5 H; 88.30, s, IH, Cl amide H; 
88.34, s, IH, Cl amide H; 88.85, s, IH, C3 amide H; 812.01, s, IH, Cll' OH. l3C (5 0 
mHz, DMSO-d6): 821.33, C9'; 33.66, ClO'; 835.01, C8'; 839.06, C6'; 856.82, C6 0 H3; 
869.90, C5'; 870.02, C4'; 870.79, C3'; 871.13, C2'; 8100.92, C5; 8103.18, qC; 8120.9 , 
qC; 8124.80, C4; 8154.88, qC; 8155.42, qC; 8168.20, qC; 8172.38, qC; 8172.56, qC; 
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OCH3 0 























11. Coupling of 9 to DoxorubicineHCl: N 1-(2-(2-(2-(3-carbamoyl-2-hydroxy-4-
methoxyphenylamino)-2-oxoethoxy)ethoxy)ethyl)-N5-((2S,3S,4S,6S)-3-hydroxy-2-
methyl-6-(( 1R,3S)-3,5, 12-trihydroxy-3-(2-hydroxyacetyl)-1 0-methoxy-6, I1-dioxo-
1 ,2,3,4,6, I1-hexahydrotetracen-1-yloxy)tetrahydro-2H-pyran-4-yl)glutaramide (16, 
Scheme 10) 
Compound 15 (286 mg, 0.65 mmol), along with HOBt (174 mg, 1.3 mmol), BOP ( 71 
mg, 1.3 mmol), and DIEA (225 ~l, 1.3 mmol) were dissolved in 25 mL DMF. After 5 
minutes, doxorubicineHCI (250 mg, 0.4 mmol) was added to the stirring solution. Th 
reaction flask was wrapped in foil and purged with N2• The flask was sealed and the 
reaction left stirring overnight. After - 21 hours, the DMF was removed under vacuu 
to give a red oil. The oil was taken up in EtOAc and triturated. A red solid precipitate 
The mixture was centrifuged and the supernatant removed. The solid was washed wit 
EtOAc twice more, each time removing the solvent by centrifugation/decanting. The r d 
product was purified via reverse-phase column chromatography (Varian Mega Bond E ut 
column) using an acetonitrile/water stepwise elution (10%, 20%, 30%, 40%, 50% 
CH3CN). Product 16 was obtained after the chromatographic separation. Yield: 270 g, 
65%. IH (500 mHz, DMSO-d6): 31.12, d, J 5.49 Hz, 3H, C16' OCH3; 31.42, d; 31.63, 
2H, m, 9' CH2; 31.83, t; 32.00, m; 32.09, m, 1 H, 10' CH2; 32.20, m; 32.95, q; 33.15, , 
2H, 6' CH2; 33.39, m, 2H, 5' CH2; 33.57, br s, 2H, 4' CH2; 33.66, br s, 2H, 3' CH2; 
33.87, s, 3 H, C6 OCH3; 33.97, s, 3H, C29' OCH3 ; M.06, s, 2H, 2' CH2 ; M.16, m; 
M.57, m; M.73, d; M.85, t; M.92, br s; 35.22, br s; 35.43, s; 36.52, d, J 8.54 Hz, 1H, 5 
H; 37.47, d; 37.62, br s; 37.75, s, 1H, C11' amide; 37.87, s; 38.15, d, J 9.15 Hz, IH, C 
H; 38.27, s, 1H, C1 amide H; 38.31, s, 1H, Cl"amide H; 38.81, s, 1H, C3 amide H; 
118 
b13.25, s, IH, C38' OH. l3C (500 mHz, DMSO-d6): b17.72, C16' CH3; b22.22, CH2; 
b30.38, CH2; b32.73, CH2; b35.30, CH2; b35.35, CH2; b37.25, CH2; b39.03, CH2; M5. 8, 
CH; b56.80, OCH3; 057.23, OCH3; 064.39, CH2; 067.36, CH2; b68.76, CH; b69.89, C 2; 
b70.02, CH2; b70.78, CH, CH2; b7 1. 10, CH2; b75.65, qC; b100.89, CH; blOL13, CH; 
b103.15, qC; b111.26, qC; b119.62, CH; b120.61, CH; b120.88, qC; b124.69, CH; 
b134.72, qC; b135.30, qC; b136.14, qC; b136.82, CH; b154.82, qC; 0155.37, qC; 
b156.78, qC; b161.42, qC; b168.16, qC; b171.77, qC; b172.52, qC (int = 2); b187.02, C. 
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12. Coupling of Fluorescein Isothiocyanate to 8: 3-(2-(2-(2-(3-(3',6'-dihydroxy-3-0 0-
3H-spiro[isobenzofuran-l,9'-xanthene]-5-yl)thioureido)ethoxy)ethoxy)acetamido)-2-
hydroxy-6-methoxybenzamide (17, Scheme 11) 
Product 8 (327 mg, 0.9 mmol) was stirred in DMP (30 mL) then DIEA (471 ilL, 2. 
mmol) was added. After 5 minutes, a homogeneous solution formed and fluorescein 
isothiocyanate (PITC; 350 mg, 0.9 mmol) was added. The reaction stirred at room 
temperature for two hours. The solvent was removed under vacuum to leave an orang 
residue. To the residue was added 5% HCI (aq) and an orange precipitate immediatel 
formed. The solid was collected via vacuum filtration and rinsed with 5% HCI then 
water. The product was dried over CaS04 overnight. Crude Yield: 330 mg, 51 %. 
Approximately 70 mg of crude material was dissolved in methanol, stirred with a 
small amount of Dowex 50x8 resin for 5 hours, filtered, and finally evaporated to dryn ss 
to give product 17 as an orange powder. Yield: 50 mg, 71 %. lH (500 mHz, DMSO- 6): 
83.68, m, 8H, 3' CH2/ 4' CH2/ 5' CH2,/6' CH2; 83.87, s, 3H, C6 OCH3; 84.11, s, 2H, 2 
CH2; 86.55, d, J 9.03 Hz, IH, C5H; 86.56, d, J 8.66 Hz, 2H, CIT H; 86.60, d, J 8.66, H, 
C18' H; 86.67, d, J 2.10, 2H, C20' H; 87.16, d, J 8.30 Hz, IH, CIO' H; 87.73, d J 8.30 
Hz, IH, C9'H; 88.10, br s, IH, CI3'H; 88.16, d, J 9.03, IH, C4 H; 88.28, s, 2H, C6' 
NH/Cl amide H; 88.32, s, IH, Cl amide H; 88.88, s, IH, C3 amide H; 810.04, s, 
phenolic H; 810.12, br s, phenolic H. \3C (500 mHz, DMSO-d6): 844.30, C6'; 856.80 
C6 OCH3; 869.24, C5'; 870.13, C4'; 870.81, C3'; 871.18, C2'; 8100.92, C5; 8102.92, 
CH; 8103.19, qC; 8110.42, qC; 8113.30, CH; 8117.01, CH; 8120.87, qC; 8124.88, C4; 
8127.20, qC; 8129.76, CH; 8130.10, CH; 8152.57, qC; 8154.94, qC; 8155.43, qC; 
124 
8160.20, qC; 8168.21, qC; 8169.22, qC; 8172.54, qC; 8181.23, qC. Mass calculated: 
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13. Carboxyalkylation of Genistein: tert-butyl 2-(4-(5,7 -dihydroxy-4-oxo-4H-
chromen-3-yl)phenoxy)acetate (18, Scheme 12) 
Genistein (2.00 g, 7.6 mmol) was dissolved in 160 mL of DMF along with potassium 
tert-butoxide (880 mg, 7.6 mmol), potassium iodide (64 mg, 5 mol%), and 18-crown-
ether (20 mg, 1 mol %). The reaction solution was stirred at 40°C under argon for 2 h urs 
before adding tert-butyl bromo acetate (2.81 mL, 19 mmol). The reaction was left stir ing 
under argon at 40°C for 2 days. The solvent was then removed under vacuum to give 
brown oil. The oil was diluted with water and then acidifies with 5% aqueous 
hydrochloric acid. A mixture of white precipitate and sticky yellow solid was obtaine as 
product 18. The product was used immediately in the next step without purification. H 
(500 mHz, DMSO-d6): 81.43, s, 9H, 3' t-butyl; 84.81, s, 2H, I" CH2; 86.38, d, J 1.83 z, 
IH, C6 H; 86.61, d, J 1.83 Hz, IH, C8 H; 86.83, d, J 8.30 Hz, 2H, C3' H IC5' H; 87.3 , 
d, J 8.30 Hz, 2H, C2' H/C6' H; 88.38, s, IH, C2 H; 89.61, C4"OH; 812.95, C5 OH. 
13C (500 mHz, DMSO-d6, determined from HMBCIHMQC data): 828.39, t-butyl; 865 97, 
C1"; 882.26, C3"; 893.76, CH; 899.15, CH; 8115.78, C3'IC5'; 8121.86, qC; 8123.50, C; 
8130.88, C2'IC6'; 8155.26, CH; 8158.19, C8a1C4; 8162.64, qC; 8164.28, C7; 8167.80 



































































































14. Acidolysis of 18: 2-(5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-
yloxy)acetic acid (19, Scheme 13) 
Product 18 was stirred in 15 mL of DCMITFA (2: 1) for 2 hours. An off-white precipi ate 
was noted. The solvent was removed via rotary evaporation and the resulting solid wa 
once again treated with the DCMITFA solution, this time for 1 hour. After the solvent 
was removed a second time, the solid was stirred in DCM and subjected to rotary 
evaporation once more. An off-white solid was collected. To remove some impurities, 
the solid product was stirred in a minimal amount of 10% methanol in chloroform, gen ly 
heated, and filtered to give a white solid product, 19. Yield: 580 mg, 23.3%. lH 500 
mHz, DMSO-d6): 84.85, s, 2H, Cl" H; 86.41, d, J 2.10 Hz, IH, C6 H; 86.66, d, J 2.20 
Hz, IH, C8 H; 86.83, d, J 8.54 Hz, 2H, C3' H IC5' H; 87.39, d, J 8.42 Hz, 2H, C2' HI 6' 
H; 88.41, s, IH, C2 H. 13C (500 mHz, DMSO-d6): 865.58, Cl"; 893.80, CH; 899.l1, 
CH; 8106.37, qC; 8115.77, C3'IC5'; 8121.70, qC; 8123.22, qC; 8130.87, C2'IC6'; 
8155.22, C2; 8158.02, qC; 8158.18, qC; 8162.41, qC; 8164.33, qC; 8170.17, qC; 8181. 2, 














Yield 580 mg, 23.3 % 
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15. Coupling of 19 to Bone-Targeted miniPEG: 2-hydroxy-3-(2-(2-(2-(2-(5-hydro y-
3-( 4-hydroxyphenyl)-4-oxo-4H-chromen-7-
y lox y )acetamido )ethox y )ethox y )acetamido )6-methox ybenzamide (20, Scheme 14) 
Product 19 (250 mg, 0.8 mmol), compound 8 (see scheme 3; 273 mg, 0.8 mmol), and -
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride ("EDC", 230 mg, 1.2 
mmol) were dissolved in 20 mL DMF. To the stirring solution was added DIEA (557 L, 
3.2 mmol). The reaction was allowed to proceed at room temperature for 18 hours. T e 
mixture was evaporated to dryness in vacuo to leave a brown oil. The oil was diluted 
with water, acidified with 5% aqueous HCI, and extracted into ethyl acetate three time . 
The organic extracts were combined then dried over sodium sulfate, filtered, and 
concentrated via rotary evaporation to yield a cloudy yellow oil. Upon trituration in 
methanol, a white solid (20) precipitated out and was collected via vacuum filtration. 
Yield: 90 mg, 22%. IH (500 mHz, DMSO-d6): 83.33, m, 6' CH2; 83.51, t, J 5.61 Hz, 
2H, 5' CH2; 83.62, m, 2H, 4' CH2; 83.70, m, 2H, 3' CH2; 83.86, s, 3H, C6 OCH3; 84.0 , 
s, 2H, 2' CH2; 84.61, s, 2H, 8' CH2; 86.41, d, J 1.83 Hz, 1H, ClO' H; 86.51, d, J 9.27 
1H, C5 H; 86.61, d, J 1.83 Hz, C18' H; 86.82, d, J 8.66 Hz, 2H, C22'H/C24'H; 87.39, , 
J 8.42 Hz, 2H, C21'H/C23'H; (38.16, m, 2H, C4 H/C6' amide H; 88.27, s, IH, Cl ami e 
H; 88.32, s, IH, Cl amide H; 88.39, s, 1H, C3 amide H; 89.60, s, 1H, C23' OH; 812.9 , 
s, IH, C11' OR. 13C (500 mHz, DMSO-d6): 838.96, CH2; 856.78, C6 OCH3; 867.80, 
CH2; 869.55, CH2; 870.03, CH2; 870.76, CH2; 871.09, CH2; 893.81, CH; 894.44, qC; 
899.34, CH; 8100.84, C5; 8115.78, C22'/24'; 8116.39, qC; 8124.65, C4; 8130.87, 
C21'IC23'; 8131.52, qC; 8154.36, qC; 8154.85, qC; 8155.19, CH; 8155.94, qC; 8158.1 , 
137 
qC; 8162.33, qC; 8164.08, qC; 8167.50, qC; 8168.14, qC; 8172.56, qC; 8181.08, qc. 
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IV. RESULTS AND DISCUSSION 
A. Synthesis 
All of the novel bone-targeted compounds synthesized for this project are summarized 
in Table 1. 
The two most selective and potent bone-targeted estrogen conjugates from the first 
studies were found to be BTE2-D2 and BTE2-D3 (Figure 40). Therefore, we used these 
molecules as the starting point for this project. Drs. K. Grant Taylor and Sujan Singh 
developed the synthetic methodology for the bone-targeting agents. The modified 
synthesis of bone-targeting agent 1 (previously labeled "D2") is described in the 
Experimental section. Bone-targeting agent 2 (previously labeled "D3") was purchased 
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Figure 40: Bone-targeted estrogen conjugates BTE2-D2 (left) and BTE2-D3 (right) were the lead 
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Figure 41: 'H NMR spectra of bone-targeting 
agents 1 and 2. 
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Table 1: Novel bone-targeted compounds synthesized for this project 
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1. Bone-Targeted mini-PEG Compounds 
To investigate the effects that new "spacers," or "linkers," would have on the bone-
targeted estrogens, linkers that were more hydrophilic and flexible than those previously 
used were incorporated into the conjugates. As stated in the Background section, the 
linkers of choice for this project were chosen to be 8-amino-3,6-dioxaoctanoic acid 
("mini-PEG") and its longer derivative ll-amino-3,6,9-trioxaundecanoic acid ("mini-
PEG-3"). Couplings utilizing both fluorenylmethyloxycarbonyl- ("Fmoc-") and tert-
butyloxycarbonyl- ("Boc-") protected mini-PEGs were explored. Due to the volatility of 
the side-products (isobutylene and carbon dioxide) formed during Boc-deprotection, it 
was originally thought that Boc-mini-PEG would be the more logical choice for use in 
these syntheses. Unexpectedly, the Fmoc-mini-PEGs gave more consistent and 
satisfactory results. Use of the Boc-protected compounds was complicated by a 
necessary dicydohexylammonium ("DCHA") desalting process and it was difficult to 
remove the all of the DCHA. Consequently, Fmoc-chemistry was employed in the 
synthesis of all of the bone-targeted mini-PEG compounds (henceforth referred to as 
"BT-MPs"). 
Four new potential "shelf-stable" bone-targeted compounds were synthesized as 
potential "universal" linkers. Figure 42 summarizes the BT -MPs. In the case of BTA 1, 
both the mini-PEG and mini-PEG-3 were effectively coupled to the bone-targeting agent. 
The attempts to couple the mini-PEG-3 linker to BTA 2 were unsuccessful. 
Three of the four new bone-targeted compounds have basic termini through which a 
drug-conjugate could be formed. The most synthetically facile of these three compounds 
was found to be 2-(2-(2-(3-carbamoyl-2-hydroxy-4-methoxyphenylamino)-2-
147 
oxoethoxy)ethoxy)ethanaminium chloride (8, Figure 42). Therefore, glutaric anhydride 
was coupled to the end of that compound to give a bone-targeted entity with an acidic 










I ~ NH2 
OCH3 0 
9 8 
Figure 42: Bone-targeting agents 3-amino-2-hydroxy-6-methoxybenzamide (1) and 3-amino-6-benzyloxy-
2-hydroxybenzamide hydrochloride (2) were linked to mini-PEG molecules. 
148 
OCH3 0 
Figure 43: Product 15. Glutaric anhydride was coupled to compound 8 (figure 9) to give a bone-targeted 
molecule with an acidic terminus. 
As shown in Table 2 of the BT-MPs, the compound arising from 3-amino-2-
hydroxy-6-methoxybenzamide (1) and Fmoc-mini-PEG gave the most acceptable results. 
Relatively high yields were accomplished for both the coupling and Fmoc-deprotection 
processes. Most importantly, no chromatographic purification was necessary for either of 
these products. Instead, all of the products precipitated nicely out of methanol. 
149 
0 
~ H 0 O~ N" ~O~, ~O~ /Fmoc HO O~ Fmoc 
HO 0 N 
H 





miniPEG Coupling Yield: 73% miniPEG Coupling Yield: unable to 
#' NH2 determine 
Fmoc-deprotection Yield: 90% 




OH miniPEG Coupling Yield: 70% 
I 
#' NH2 Fmoc-deprotection Yield: 57 % 
N/A 
OBz 0 
Table 2: Summary of synthetic results from bone-targeted mini-PEGS and estradiol conjugates 
All of the amide couplings were performed with the condensing agents 
hydroxybenzotriazole ("HOBt") and benzotriazole-l-yl-oxy-tris-(dimethylamino)-
phosphonium hexafluorophosphate ("BOP") in DMF using diisopropylethylamine 
("DIEA") as a base. Equimolar amounts of carboxylic acid and amine seemed to be 
sufficient for the couplings, while an excess of coupling agents (1.3-2 times) and a two-
fold excess of base gave satisfactory yields in most cases. It was noted that after the 
reaction, complete removal of DMF was imperative for successful product isolation. 
Most completed reaction mixtures were left under vacuum «10 mm Hg) while on a 
150 
rotary evaporator set at 35-40°C for one hour before and after reaction work-up. Only 
after all of the DMF was removed would the products precipitate from methanol. 
Although the formation of amide bonds can sometimes be troubled by the presence of 
water due to its role as a competing nucleophile, rigorously anhydrous conditions were 
found not to be necessary for these particular couplings. The use of reagent grade 
solvents and fresh reagents appeared to be adequate for acceptable yields. No difference 
was observed when the reactions were performed under an inert atmosphere. 
Figure 44 shows the I-dimensional 'H NMR spectra obtained from products 8, 9, and 
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Figure 44: I-dimensional IH NMR spectra of BT-MPs 
8,9, and 11. 
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2. Bone-Targeted Estrogen Conjugates 











¢C;0H ~ctcn° I 0 # NH2 





















Table 3: Bone-targeted estradiol conjugates 
The same reaction and work-up conditions were used for these couplings as employed 
for making the BT-MPs. Although all three of the BT-MPs did yield a novel drug 
conjugate when coupled to ~-estro-O-propanoic acid, product 12 was synthetically less 
complicated to isolate than products 13 and 14. After work-up, 12 precipitated 
immediately when triturated in methanol, giving a clean solid product. Product 13 could 
153 
only be collected after sitting in hexane for some length of time, on the order of weeks, at 
4° C. Although it precipitated out purely, the yield was very poor - only 14%. Finally, 
14 was produced in a moderate yield, but did require chromatographic separation. 
The couplings were monitored by lH NMR spectroscopy. Upon the formation of the 
amide bond, a correlation could be observed in the COSY spectrum between the terminal 
NH proton of the BT -MP and its neighboring methylene protons. Also, a downfield shift 
could be noted in the terminal methylene protons in the I-dimensional spectrum when the 
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Figure 45: The through-bond coupling interaction between the protons highlighted in red can be observed 
in the COSY spectrum of the newly formed conjugate. 
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Figure 46: A downfield shift could be noted in the terminal methylene protons 
(rcd) in the I -dimensional spectrum when the amide formed. 
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It was discovered that the replacement of the O-methyl group at carbon 6 (as in 1) with 
an O-benzyl (as in 2) gave no significant advantage to the biological activity of the 
estradiol conjugates (discussed in next section). That information, coupled with the 
pleasing synthetic outcomes, led to the decision that future drug conjugates would be 
made from the bone-targeting agent 1 and mini-PEG scaffold. Thus, compound 8 
(below) became the sought-after "shelf-stable" bone-targeting entity. 
o 
~ Jtf
8 + Cl 
HN O~~ 3 o 
8 
OCH3 0 
Figure 47: Because of the successful synthetic outcomes from the Fmoc-mini-PEG 
coupling, the Fmoc-deprotection, and estradiol conjugate formation, compound 8 
would be used as the bone-targeting entity for future drug conjugates. 
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3. Bone-Targeted Doxorubicin Conjugate 
In order to synthesize a conjugate of the anticancer dmg doxmbicin (see Figure 48), the 
acidic 15 shown in Figure 43 was coupled to the amino sugar of the doxorubicin 







Figure 48: Doxorubicin. The bone-targeted conjugate utilized the amino group highlighted in red . 
Although the estradiol conjugate of 8 precipitated out nicely from methanol after the 
reaction work-up, the doxorubicin conjugate of 15 displayed dramatically different 
behavior. After the DMF was removed from the reaction mixture, the remaining red 
residue was found to be insoluble in ethyl acetate and other typical organic extraction 
solvents, To remove excess coupling agent, the product was stirred in EtOAc, and then 
centrifuged and the supernatant removed, This process was repeated several times. 
Finally, reverse-phase column chromatography had to be employed to separate unreacted 
doxombicin from the drug conjugate. The described methodology yielded a product of 
high purity, Analogous to the estradiol conjugates, 1- and 2-dimensional l H NMR 
157 
spectroscopic analysis was used for to confirm amide bond formation between 8 and 
doxorubicin. 
4. Bone-Targeted Fluorescein 
Making a bone-targeted conjugate of fluorescein proved to be more challenging. 
Initially, we wanted to use an amide bond to link a BT-MP to a fluorophore. Amide 
bonds are less susceptible to degradation than esters and easier to form than ethers or 
esters. The first fluorescent molecule of choice was 5-aminofluorescein ("SAF"; Figure 
49). When the standard procedure used for amide bond formation in this project 
(HOBt/BOP coupling in DMF with DIEA) was attempted with 5AF, a side-reaction 
between the BOP reagent and SAF was noted. An additional complication arose from the 
fact that 5AF exists in an equilibrium between a lactone and an open-chain quinoid 
(Figure 50). Because this equilibrium is pH dependent, the solubility properties of the 
molecule also change with pH. When the coupling reaction was worked-up as usual, the 
product was distributed between the aqueous and organic layers. To avoid this difficulty, 
a new synthetic scheme was proposed (see Scheme 15). First, esterification of the open-
chain tautomer of the 5AF molecule as described in the literature (Burchak, et aI, 2006), 
would "lock" the molecule into one tautomeric form (it happens that the open-chain 
quinoid form of SAF is the form in which the molecule is fluorescent.) Subsequently, 
amide bond formation could take place at the 5-amino position using acidic BT-MP 15. 
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Scheme 15: Proposed synthetic strategy for making bone-targeted fluorophore. 
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While the esterification was accomplished with moderate success (65% yield), the 
coupling step seemed to yield some undesired ester product at the remaining phenolic 
position. Instead of trying to block the phenolic position after esterification, it was 
decided to try alkylating that position with t-butyl bromo acetate and then cleaving the 
ester to get a carboxylic acid functionality (Scheme 16). Since the second strategy would 
not make use of the amino group on the 5AF molecule, it was proposed to try the 
synthesis on fluorescein itself. However, the new synthetic scheme was quickly 
abandoned after the esterification of fluorescein lead to an alkylated product at the 
phenolic position. 
HO 




Scheme 16: Strategy 2. Esterify fluorescein, alkylate at phenolic position, then finally conjugate through 
acidic functionality. 
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Once again, the synthetic approach was modified. Employing the commonly used 
fluorescein isothiocyanate (FITC), a bone-targeted fluorophore was quickly synthesized, 
as described in the Experimental section. The FITC conjugate of 8 is linked via a 
thiourea bond, a more labile bond than an amide. However, Wang, et al (2003) published 
a study in which a FITC-labeled bone-targeted conjugate was investigated in vivo and 
biodegradation was not a problem. 
Although the coupling of the bone-targeted miniPEG went quickly and resulted in an 
acceptable crude yield (51 %), it was obvious from 'H NMR characterization that a 
significant amount of diisopropylethylamine was still present in the crude material. 
Subjecting the solid to strong vacuum, even for long periods of time, did not eliminate 
the residual base. With the hopes of removing the DIEA via ionic interactions, the crude 
substance was dissolved in methanol, stirred with Dowex 50x8 resin for several hours, 
and then filtered. After the methanol was removed, the orange powder that resulted 
appeared to be free of DIEA. 
While the NMR spectra of product 17 do show a small amount of DMF and methanol 
left in the solid, the removal of these solvents is much more straightforward than is DIEA 
removal. Also, the relative amount of DIEA left after the reaction compared to DMF is 
much greater. Collectively, the chemical investigations with fluorescein resulted in the 
development of synthetic and purification protocols for a bone-targeted fluorophore. 
Fluorescence spectra of 17 revealed maximum excitation occurred at A=495 nm and 
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Figure 51: Fluorescence excitation (top) and emission (bottom) spectra of product 17. Emission spectrum 
obtained by excitation at A = 495 nm. 
163 
5. Bone-Targeted Genistein 
To make genistein (Figure 52) compatible for coupling to 8, a regioselective 
alkylation of the tri-phenolic molecule was first needed. Of the three phenol groups that 
genistein possesses, the 7 -OH is the most acidic. Lewis, et al (2000) report that this 
hydroxyl group is 100 fold more acidic than the 4' -OH due to the electron withdrawing 
effect of the carbonyl at C4. By exploiting this difference in pKa, genistein and other 
isoflavones have been selectively alkylated (Lewis, et a12000; AI-Maharik, Kaltia, and 
WahaIa, 1999; Wang, et aI2005). The phenolic proton at the 5-position is typically not 
reactive due to the hydrogen bonding interactions with the adjacent carbonyl. 
HO 
OH 
Figure 52: Genistein. 
Since the 7-0H is substantially more acidic than the 4' -OH, the addition of one 
equivalent of base should only deprotonate the 7-0H. Simultaneous addition of the 
alkylating agent should cause the reaction to proceed selectively at the 7-position (see 
Figure 53). If alkylation is desired at the 4' -position, the dianionic species must first be 
generated by the addition of two or three molar equivalents of base. Because the less 
acidic phenolic group should result in the more nucleophilic anion, subsequent treatment 
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Figure 53: Options for the regioselectivealkylation of genistein. 
For the purposes of this project, the position at which the alkylation occurred was 
not of great consequence, so long as the reaction proceeded selectively. A synthetic 
scheme based on the work by AI-Maharik, Kaltia, and Wahala (1999) was proposed (see 
Scheme 17). In the published reference, genistein was alkylated selectively either at the 
7- or 4' -position with ethyl bromo acetate under the applicable conditions. The ethyl ester 
was then cleaved via acidolysis to yield the corresponding carboxylic acid. To make the 
precursor for the bone-targeted genistein, it was decided that tert-butyl bromoacetate 
would be used instead of ethyl acetate, simply because t-butyl esters cleave easily with 






Scheme 17: Proposed synthetic scheme for selectively alkylating genistein with t-butyl bromoacetate. 
OH o 
OH 
Optimizing the reaction conditions for the alkylation proved to be a nontrivial task. 
Potassium t -butoxide was determined to be a better base than potassium carbonate for 
this particular reaction. Equimolar amounts of base and genistein were used when the 
reaction was run at high temperature to alkyl ate position 7, while a 3 to 1 stoichiometric 
ratio was employed for alkylation at the 4' -position at low temperature. For alkylation at 
the 7-0H, it was found that 2 to 1 stoichiometry of alkylating agent to genistein resulted 
in more product than 1 to 1 stoichiometry. Using excess alkylating agent in the presence 
of excess base lead to the formation of a dialkylated species. The addition of both 18-
crown-6 ether as a potassium ion scavenger and potassium iodide as an iodide source 
seemed to improve both reaction speed and yield. 
The formation and isolation of product 18 (Figure 54), the 7-0 alkylated product, was 
the most facile of the possible synthetic choices. Although some impurities were 
observed in the thin-layer chromatography of the alkylated product, the IH NMR 
spectrum revealed that these were minimal (see Figure 55). Chromatographic separation 
at this point was ineffective. Superior purification was achieved after the acidolysis 
performed in the next step. As described in the Experimental section, the acidic genistein 
species generated after acidolysis could easily be purified by stirring in warm solvent and 
filtering, although it is still unclear if the purification at this step is necessary for 
successful coupling to the bone-targeted miniPEG. 
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Figure 54: Alkylated genistein product 18. 
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Figure 55: IH NMR of alkylated genistein product 18. Since the impurities at this point appeared 
to be minimal, the crude material was used immediately in the next step. 
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The regioselectivity of the reaction was confirmed via HMQC/HMBC experiments. 
The observable couplings of C7 and protons 6 and 8 validated the correlation between C7 
and the 1" protons, therefore ensuring that alkylation took place at the 7 position. The 
HMBC spectrum is shown in Figure 56. It appeared that no alkylation took place at the 
4' position under these conditions. 
During the exploration of fluorescein chemistry, a side reaction was noted between the 
5-aminofluorescein quinone system and BOP. Also, the use of HOBt and BOP as 
coupling agents requires a base wash during the work-up. Under basic conditions, 
deprotonation of the 5-0H group is possible and the product could end up in the aqueous 
layer. With these issues in mind, coupling of the genistein acid to compound 8 was 
performed with l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride ("EDC") 
instead of the HOBt and BOP used for the other conjugates. 
The final bone-targeted product precipitated out of methanol to give a clean solid. 
Undesirably, IH NMR spectroscopy revealed that the polar product was distributed 
between the aqueous and organic layers, resulting in a low yield. It may be possible to 
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v. SUMMARY 
Ten novel bone-targeted molecules were designed, synthesized, purified, and 
characterized: four bone-targeted ("BT") miniPEG derivatives, three BT -estrogens, a 
BT-doxorubicin, a BT-fluorescein, and a BT-genistein. Fmoc-protected miniPEGs were 
preferred over Boc-protected miniPEGs. Three of the bone-targeted miniPEGs had basic 
termini, while the fourth had an acidic terminus. The basic BT-miniPEGs appeared to be 
stable as HCl salts. 
Because of the successful synthetic results, compound 8, with a basic terminus, was 
chosen for use in future BT -drug conjugates. Its acidic counterpart, 15, was developed 
out of necessity during the design of a BT -doxorubicin. Hence, this project led to the 
development of two new "universal" bone-targeting agents. 
Although no formal assessment of water-solubility was performed, it was apparent 
from experimental observation that the miniPEG-linked estrogens were more hydrophilic 
than those with no miniPEG linker (i.e. the bone-targeted estrogens from previous 
studies). During reaction work-ups, often times the conjugated products would appear in 
both the aqueous and organic layers. Also, a direct comparison showed that the older 
generation conjugates with no miniPEG linker dissolved more readily in organic solvent 
than the miniPEG-linked conjugates. 
To demonstrate the potential of the "universal" bone-targeting agents, as well as 
produce additional prospective therapies, conjugates of doxorubicin, fluorescein, and 
genistein were synthesized. Genistein required a regioselective alkylation and 
subsequent acidolysis to be compatible for coupling to the bone-targeted miniPEG. The 
reaction conditions for each conjugate were optimized. Each of these conjugates 
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displayed significantly different solubility properties and, consequently, demanded 
different methods of isolation and purification. 
Biological evaluation * of some of the BT -conjugates was performed. The procedures 
and results are discussed in the appendices (pp. 186-199). In vivo testing of all three BT-
estrogens revealed that although some extraosseous effects were observed, the conjugates 
appeared to preserve bone density in ovariectomized rats and possibly even had an 
anabolic effect. In vitro studies showed that the bone-targeted doxorubicin conjugate 
maintains the potency of the parent doxorubicin compound. 
* Biological studies of the bone-targeted estradiol conjugates were performed by the 
following persons from the University of Louisville: Department of Pharmacology and 
Toxicology: Dr. Kevyn Merten, Dr. Jian Cai, and Ned Smith; Department of Physiology: 
Dr. Jeff Falcone and Kathleen Hamilton; Department of Orthopaedic Surgery: Dr. 
Michael Voor and Qian Xiao. Biological evaluation of the bone-targeted doxorubicin 
was performed at Tufts University in the laboratory of Michael Rosenblatt M.D. 
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VI. FUTURE DIRECTIONS 
To reduce extraosseous effects from the bone-targeted estrogens, a third generation of 
conjugates wi ll be synthesized, These conjugates wi ll be phosphorylated at the phenolic 
3-position of the estradiol molecule (see below). The rationale behind such a 
modification is that the phosphorylated conjugate would not be activated until hydrolyzed 
via a phosphoesterase in the bone. Unwanted estrogenic effects on the uterus cou ld 
possibly be avoided by treatment with a prodrug of this kind, as accumulation of the 
conjugate in the bone tissue and in situ hydrolysis would minimize exposure to the 
reproductive organs. 
~ 








Biological testing will also be performed on the bone-targeted genistein compound. 
The bone-targeted doxorubicin will be subjected to in vivo analysis . The bone-targeted 
fluorescein will be used in imaging studies to further investigate where the bone-targeted 
compounds are distributed in vivo. Future synthetic work will be decided after the 
biological data from these compounds is collected. By employing infrared spectroscopy, 
it is anticipated that some insight may be gained into the structural characteristics of the 
compounds whi le bound to hydroxyapatite. 
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1. In Vivo Biological Studies of Estradiol Conjugates 
Biological studies of the bone-targeted estradiol conjugates were performed by the 
following persons from the University of Louisville: Department of Pharmacology and 
Toxicology: Dr. Kevyn Merten, Dr. Jian Cai, and Ned Smith; Department of Physiology: 
Dr. Jeff Falcone and Kathleen Hamilton; Department of Orthopaedic Surgery: Dr. 
Michael Voor and Qian Xiao. 
Animals 
In Vivo Experimentation 
Methods and Materials 
Six month old, bilaterally ovariectomized (OVX) or sham operated Sprague-
Dawley female rats (Harlan Laboratories, Indianapolis, IN) were maintained at the 
University of Louisville Research Resources Center at 22°C with a 12-h light/dark cycle 
and ad libitum access to tap water and rodent chow (Purina Laboratory Rodent Diet 
5001). All animal procedures were approved by the Institutional Animal Care and Use 
Committee, which is certified by the American Association for Accreditation of 
Laboratory Animal Care. 
Experimental Design 
Three in vivo experiments were conducted in order to investigate the therapeutic 
effects of second and third generation bone-targeted estrogens (BTE). In all of the 
experiments, OVX and sham operated rats were randomly divided into groups of 5-7 
animals. In all of the studies experimental groups included i) Sham-operated control 
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(euthanized six weeks post surgery as a pretreatment control), ii) OVX control 
(euthanized six weeks post surgery as a pretreatment control), iii) Sham control receiving 
vehicle, iv) OVX control receiving vehicle, v) OVX receiving 17-ethinyl estradiol 
(equimolar concentration with a selected BTE group), vi) OVX receiving alendronate 
(1.6 mg/kg), and vii) OVX receiving parathyroid hormone 1-34 (PTH) (80 Ilg/kg). All 
drugs and vehicle (1 % DMSO in corn oil) were administered three times per week orally 
by gavage except for PTH which was administered via a subcutaneous injection in a 
volume of 0.5 mllkg body mass thrice per week. Drug administration was initiated 6 
weeks following surgery and lasted for 6 weeks (18 doses total). 
In the first study (Study 07 XP 2) a second generation BTE, BTE2-pg2-D2, was 
orally administered to OVX rats at doses of 10, 100, or 1000 Ilg/kg (vehicle = 1 % DMSO 
in corn oil). In the second study (Study 07 XP 3) the second generation BTE, BTE2-pg3-
D2, was orally administered to OVX rats at doses of 10, 100, or lOOOllg/kg. In the third 
study (Study 07 XP 4) the second generation BTE, BTE2-pg2-D3 was orally administered 
to OVX rats at doses of 10, 100, or 1000 Ilg/kg and two third generation BTE's, BTEr 
D2-3-0-DBtP and BTErD2-3-0-DBnP were orally administered to OVX rats at doses of 
25 and 250 Ilg/kg. As indicated above all BTE's were administered three times per week 
for 6 weeks. 
Following 6 weeks of treatment, blood was obtained from each animal via cardiac 
puncture following an overnight fast and animals were subsequently euthanized via 
carbon dioxide asphyxiation. Blood was centrifuged immediately and the obtained serum 
samples were aliquoted and stored at -700 C prior to analysis. Uteri were removed and 
fresh weights were obtained. Uterine masses were normalized to body mass at the end of 
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the experiment. The left and right femora and left and right tibiae were subsequently 
collected from each animal, cleaned of soft tissue, and stored in saline at 4 DC prior to 
analysis. 
Femoral Density via Archimedes' Principle 
Right femora were submerged in distilled water and fully hydrated under a 
vacuum for 1 hr. Subsequently, the mass of each hydrated femur was obtained in air and 
when submerged in water. Densities were determined using Archimedes' Principle 
according to the following formula: density = [mass of hydrated femur / (mass of 
hydrated femur - mass of hydrated femur submerged in water)] x density of distilled 
water at a given temperature (1). 
Regional Femoral Density via Archimedes' Principle 
The proximal and distal ends of the femur are comprised primarily of 
cancellous/trabecular bone, whereas the femoral diaphysis contains primarily cortical 
bone. Evaluation of the density of each of these femoral regions may thereby increase 
our understanding of the effect of a drug on each of these types of bone. The left femora 
were separated into three regions (proximal left femur, distal left femur, and left femoral 
diaphysis) using an Isomet Low Speed Precision Sectioning Saw from Buehler Limited 
(Lake Bluff, IL) with a diamond blade. Briefly, each femur was measured with a Cen-
Tech Digital Caliper and a cut was made from each end at 20% of the length of the femur 
plus half the width of the blade. Subsequently, the bone marrow was washed out of the 
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femoral diaphysis and the Archimedes density for each of the three femoral regions was 
determined as described above. 
Ex vivo micro-computed tomography (J..LCT) 
Volume fraction is a representative value for the amount of bone that occupies a 
given volume or space. High resolution image data were collected using a customized 
micro-CT system (ACTIS 1501225 system, BIR Inc., Lincolnshire, IL). The metaphysis 
of each right tibia was scanned over a three millimeter range and three-dimensional 
images were reconstructed. Data were subsequently processed to reveal the volume 
fraction (BVrrV) occupied by trabecular (cancellous) bone tissue, cortical bone tissue, 
and whole bone tissue. 
Bone Mechanical Competence Indentation Test 
After sacrifice, the left tibiae were trimmed to expose the cancellous bone of the 
proximal tibial metaphysis and an indentation test was performed by advancing a flat-
tipped cylindrical post (l.5 mm diameter) axially into the cut surface to measure the 
compressive strength of the cancellous bone structure. 
Rat Osteocalcin EIA 
Osteoca1cin is a hydroxyapatite-binding protein that is synthesized by osteoblasts 
during bone formation. Thereby, serum osteoca1cin levels are commonly used as a 
biochemical marker of bone formation. Rat serum osteoca1cin levels were measured 
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using the Rat Osteocalcin EIA Kit from Biomedical Technologies, Incorporated 
(Stoughton, MA) as recommended by the manufacturer. 
RatLapsTM ELISA for C-telopeptide Fragments of Collagen Type I (CTX-I) 
Osteoclast mediated breakdown of collagen type I in bone leads to the release of free and 
peptide bound fragments of the collagen type I molecule. The fragment released from the 
carboxy-terminal region of collagen type I is termed the C-telopeptide fragment of 
collagen type I (CTX-I) and is commonly used as a biochemical marker of bone 
resorption. Bone resorption (CTX-I) was quantitatively assessed in rat serum using the 
commercially available RatLaps ™ ELISA KIT from Nordic Bioscience Diagnostics A/S 
(Herlev, Denmark) as recommended by the manufacturer. 
Quantitative Determination of Lipid Metabolism (Total Cholesterol, HDL, and 
LDL) in Rat Serum 
Total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) 
were quantitatively determined in the serum of rats in order to evaluate the extraosseous 
effects of estrogen treatment on lipid metabolism. Commercially available kits from 
Wako Diagnostics (Richmond, VA) were used for the evaluations as recommended by 
the manufacturer. 
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[1] Keenan MJ, Hegsted M, Jones KL, Delany JP, Kime JC, Melancon LE, Tulley RT, 
Hong KD. Comparison of bone density measurement techniques: DXA and Archimedes' 
principle. J Bone Miner Res 1997;12:1903-7. 
Results and Discussion 
Ovariectomy (OVX) is a surgical removal of the ovaries. Six-month old female 
rats underwent either sham or OVX surgery at time equals zero. OVX animals gradually 
lose bone over time due to decreased estrogen levels as would be seen in women with 
postmenopausal osteoporosis. After six weeks a group of OVX animals and a group of 
sham animals were sacrificed. After 6 more weeks (12 weeks total) another OVX group 
and another sham group were sacrificed. At the six-week time point following OVX, 
drug administration was initiated. At that point, the drug was administered for six weeks, 
three times per week for a total of eighteen doses. Micro-computed tomography 
(microCT) scans (Figure 57) show the bone loss that occurs in the tibia following OVX 
surgery. Similar scans were taken for bones treated with osteoporosis drugs currently 
being prescribed (Figure 58) and those treated with our novel drug conjugate 13 (Figure 
59). 
Archimedes density measurements of the right femur were taken to assess bone 
density (Figure 60). When administered in vivo to OVX rats, conjugate 13 was shown to 
preserve femoral bone density in a dose-dependent fashion. The conjugate was found to 
maintain bone density as well or better than 17 -p-estradiol ("OVX + 17 EE") or 
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Figure 57: Micro-computed CT scans show the effect of 
OVX on bone density. 
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Figure 58: Effects of available treatments for osteoporosis after 6 
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Figure 59: Effects of estradiol conjugate 13 (BTE2-pg3-D2) 
after 6 weeks of administration. 
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Figure 60: When admini stered ill vil'o to OVX rats. conjugate 13 (BTE2-pg3-D2) was shown to preserve 
f~ l1l o ra l bone density in a dose-dependent fashion. Note that at the two higher doses, the estroge n 
conj ugale main lai ns bone densilY as we ll or beller lhan 17-p-eslradiol ("OYX + 17 EE") or parat hyroid 
hormone ("OYX + PTH"), 
The mechanical strength of the bone was measured via a blunt force indentation tes t in 
which a fl at-tipped cylindrical post is advanced into the trabecular bone until the bone 
breaks (see Figure 61), A dose-dependence was also noted fo r the preservation of the 
mechanical competency of the bone when 13 was administered orally to OYX rats for a 
period of six weeks, The mechanical strength of the tibia was found to be comparable to 
that seen foll owing treatment with the bisphosphonate alendronate and parathyroid 
hormone, 
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Study 07 XP 3 . Ind enta t ion Test 
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Figure 61: A close-dependence was also noted for the preserva tion of the mechan ical co mpetency of the 
hone when 13 (BTE2-pg3-D2) was admini stered oral ly 10 OVX rat s fur a peri od of six weeks) as 
delermi ned by blunt force indentati on tests. The mec hanical strength of the ti bia '>vas found to be 
comparahle 10 that see n following treatment with alencironalc (a hi sphosphonall! : "OVX + A len") and 
r aralhyroid h OnTlO IW COYX + PTH") . 
Another test pe rfo rmed on the estrogen conjugates was a measurement of osteocalcin 
in the blood (Figure 62). Anabolic drugs build bone and in the process a bone protein 
known as osteocalcin is excreted into the blood. This protein can be measured from the 
blood as a measure of anabolic potential. For example, parathyro id hormone is an 
anabolic agent and causes an increase in osteocalc in levels. At high doses, 13 
administration resulted in a much higher blood serum concentration of osteocalcin than 
estradiol treatment. Although these stud ies did not conclusively prove that we developed 
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Figure 62: At high doses, 13 (BTE2-pg3-D2) ad mini stration resulted in a much higher 
blood sa ul11 concentrati on or osteocalcin than eSlradio l trealment. dl;: l11oll Slrating 
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Upon ovariectomy, animals gain a substantial amount of weight in comparison to 
sham-operated animals. When estradiol is administered, a decrease in the body weight of 
the OYX animals is observed. This observation can be used 1.0 help determ ine if the 
bone-targeted estrogens are causing estrogenic effects outs ide of the bone. The highest 
dose of 13 causes a decrease in body weight similar to that fo llowing estrad iol (Figure 
63). Unfortunately, this indicates that our conjugate is causing un wanted effects outs ide 
of bone ti ssue, or "ex traosseous effects." 
A second ex traosseous effect of estradiol is the stimulation of the uterus, leading to an 
increase in uterine mass. By bone-targeting estradiol we would hope to prevent this 
increase in uterine mass. However, this is not the case as 13 causes a dose-dependent 
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Figure 63: The highest dose of 13 (BTE2-pg3-D2) causes a ciecrease in body weight 
similar to that following estradiol (OVX + 17 EE). 
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Figure 64: 13 (BTE,2-pl:g3-D2) causes a dose-dependent increase in uterine mass comparahlc 
to estradiol. 
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2. In Vitro Evaluation of the Effect of BT2-pg2-Doxorubicin and Free Doxorubicin 
on SUM1315 Human Breast Cancer Cells 
Biological evaluation of the bone-targeted doxorubicin was performed at Tufts 
University in the laboratory of Michael Rosenblatt M.D. 
Materials and Methods 
Colony formation assay: 
SUM 1315 human breast cancer cells (derived from a clinical metastatic nodule) were 
seeded in 6 well plates at 5000 cells/well in 2 ml of medium. Cells were allowed to 
adhere overnight prior to drug treatment. BT2-pg2-doxorubicin (Nbr-VI) or free 
doxorubicin were added to the cells at concentrations of 0.05, 0.1, 0.5,1,5, and 10 /lM 
and cells were allowed to grow at 3TC for 10 days. In addition, untreated and vehicle 
(0.1 % DMSO) treated wells were included as controls. After 10 days of treatment, 
medium was removed from each well and cells were subsequently washed with water. 
Cells were then fixed in 10% formaldehyde for 10 minutes, washed with water and then 
stained with 0.5% crystal violet for 5 minutes. Colonies of cells were subsequently 
counted under the microscope in three separate frames. Three independent experiments 
were performed and the results are an average of the three experiments. Images are from 
one representative well for each concentration. 
Cell Proliferation Assay - MTT Assay: 
The MTT assay is a colorimetric assay that is based on the cleavage of a yellow MTT 
tetrazolium salt to purple formazan crystals by the mitochondria of metabolically active 
and viable cells. The formazan crystals are insoluble in aqueous solution but may be 
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dissolved in acid and quantified using a spectrophotometer. The number of living and 
viable cells in a sample directly correlates to the amount of purple formazan crystals 
formed. SUM1315 human breast cancer cells were seeded in triplicate in 96 well plates 
at 1000 cells/well and were allowed to adhere overnight prior to drug treatment. BT2-
pg2-doxorubicin (Nbr-VI) or free doxorubicin were added to the cells at concentrations 
of 0.05,0.1,0.5, 1,5, and 10 11M and cells were allowed to grow at 3TC for 1,2,3,4,5, 
or 6 days. In addition, untreated and vehicle (0.1 % DMSO) treated wells were included 
at each time point as controls. Following treatment the MTT assay was subsequently 
performed and the absorbance at 490 nm was recorded. Three independent experiments 
were performed and the results are an average of the three experiments. 
Results and Discussion 
Bone-targeted doxorubicin conjugate 16 was evaluated in tandem with doxorubicin-HCl 
for toxicity against SUM 1315 human breast cancer cells. The cancer cells were allowed 
to colonize overnight before being treated with either drug. Two different assays were 
performed on these cells. In the colony formation assay, the colonies were treated with 
BT -doxorubicin or free doxorubicin then left to incubate at 3]DC for ten days. Untreated 
colonies, as well as those treated with 0.1 % DMSO, were used as controls. Subsequent 
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Figure 65: Colony counts after 10 days of colony growth at various concentrations of 
drug. Dox = free doxorubicin; Nbr-VI = BT-doxorubicin conjugate 16. 
At the higher concentrations, the bone-targeted doxorubicin conjugate did seem to 
maintain the potency of the parent doxorubicin. 
The second assay performed on breast cancer cell colonies was a cell proliferation 
assay, in which cells were allowed to grow in varying concentrations of drug for either I, 
2,3 , 4,5, or 6 days at 3rc. Cell proliferation was monitored via the cleavage of 3-(4,5-
Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide ("MTT") by the mitochondria 
of active cells. Upon cleavage, a purple formazan product is formed and can be 
quantitated spectrophotometrically. The number of living and viable cells in a sample 
directly correlates to the amount of purple formazan crystals formed. The results of the 
assay using conjugate 16 and free doxorubicin after 5 and 6 days of treatment are shown 
in Figure 66. At high dosages, the bone-targeted drug conjugate appears to display a 
toxicity similar to that of free doxorubicin. 
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Figure 66: Cell proli feration data after 5 and 6 days of treatment with doxorubicin 
("Oox"; top) and conjugate 16 ("Nbr-VI"; bottom) at various concentrations. 
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Synthesis and characterization of bone-targeted drug conjugates: 
• Developed, performed, and evaluated synthetic protocols 
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